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P R E F A C E 
Systemic lupus erythematosus cont i nues to fascinate ' the 
clinician, the immunologist, the virologist, the geneticist 
and the epidemiologist. The etiological agent or agents 
remain elusive and while much is known about the pathogene-
sis of the disease there are as yet many unanswered ques-
tions. Evidence for a central role of DNA immune complexes 
in the pathogenesis of SLE has been derived from histologi-
cal, immunofluorescence and acid elution studies of the 
kidney and other organs. The presence in the circulation 
of double-stranded anti-DNA antibodies, considered to be 
virtually exclusive to SLE, and DNA i tself, provide further 
support for the role of specific DNA immune complexes in 
the disease. While a number of assay s exist for the detec-
tion of circulating antigen nonspecific complexes, there 
are by contrast very few techniques available for measuring 
specific DNA complexes, and studies correlating their 
presence with clinical activity are few. Prompted by this, 
a technique for the measurement of circulating DNA complexes 
by millipore filtration and deoxyribonuclease digestion, and 
a physicochemical assay for the detection of double-stranded 
DNA were developed. Their role in the pathogenesis of SLE 
and as monitors of disease activity were evaluated in a series 
of patients during both clinically active and inactive disease. 
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DEOXYRIBONUCLE I C ACID 
1 A physicochemical technique for the assay of dsDNA 
in plasma by polyacrylamide gel electrophoresis and 
ethidium ~romide staining was developed. 
2 The specificity of the assay was established by the 
staining and mobility characteristics, DNase and 
RNase digestion, heat denaturation and gel range 
analysis. 
3 The steps necessary to ensure that plasma used in 
the assay is free of contamination with cellular 
material are outlined. 
4 dsDNA was found to be stable at temperatures of 
between -20°c and 37°c when studied over 24 hours 
and at -20°c over a period of 4 weeks. 
5 The% recovery was 97, 84, 89 and 56 for 500, 250, 
50 and 25 ng/ml respectively. 
6 The within-group variability of plasma dsDNA levels 
showed a standard deviation of 13.8% for levels 
of 40 ng/ml and above. 
7 Serum was found to be unsuitable for dsDNA estimation 
by this method. 
8 dsDNA was undetectable in 47 of 58 normal subjects, 
with levels ranging from 10 to 54 ng/ml in the 
remaining 11 subjects. 
9 Plasma dsDNA levels measured in normal subjects over 
a 24 hour period and after exposure to UV irradiation 
showed no variation. 
10 Plasma dsDNA levels in patients with SLE were no 
different to those found in normal subjects, 
irrespective of the system involved or whether the 
disease was active or inactive. Significant 
elevation was however recorded in patients after 
haemodialysis. 
dsDNA IMMUNE COMPLEX ASSAY 
1 An assay for the detection of dsDNA immune complexes, 
based on a principle of rnillipore filtration and 
DNase digestion was developed. 
2 The degree of sensitivity of the assay was not affected 
by the presence of free anti-DNA antibody in the serum 
even at high levels. 
viii 
3 Circulating levels of DNA complexes were taken to be 
significant at a P value of less than 0.02 for levels 
of 0.03 units/ml or greater. 
4 The possibility that a proportion of the material 
detected is due to nonspecific aggregates rather than 
true DNA complex material was investigated by comparing 
levels in freshly collected serum and in serum exposed 
to conditions known to favour the formation of aggre-
gates. The data suggests that nonspecific aggregates 
do not affect the levels obtained for reasons which 
will be discussed. 
5 Complexes were undetectable in 19 (95%) of 20 normal 
subjects while in the remaining subject a level of 
only 0.03 units/ml was present .. 
6 The diagnostic value of the assay for SLE, particularly 
during active disease, was demonstrated in a compara-
tive study of a group of patients with active 
rheumatoid synovitis. 
7 Five categories, with respect to the relationship 
between free anti-DNA antibody ~nd DNA complexes in 
patients with active SLE, were found. The majority 
of patients remained"true" to category irrespective 
of the system involved with each attack, or whether 
they were tested early or late in the acute episode. 
8 The DNA complex assay was compared to the c
1
q binding 
assay in 16 patients with SLE. While the numbers 
are too small for statistical analysis, this pre-
liminary study suggests that a good correlation 
between the assays may be shown. 
9 A study of the DNA complex assay in 40 patients with 
SLE showed that: 
(i) A good correlation exists between the presence 
or absence of circulating DNA complexes and 
active or quiescent disease. 
(ii) The assay is superior to the anti-DNA antibody 
as a parameter of activity , and when evaluated 
in conjunction with CH50 and anti-DNA antibody levels a prediction of Ehe relative risk of 
active disease being present is enhanced. 
(iii) There is a good correlation between actual levels 
of circulating complexes and the degree of acti-
vity. 
(iv) The DNA complex assay is of predictive value, 
as in some cases their appearance in the cir-
culation antedates the onset of activity. 
ix 
10 The case histories and serial studies of CH
50
, 
anti-DNA antibody and DNA complex levels in 
9 patients with SLE during active and inactive 
disease are presented to illustrate the interesting 
variations which occur. 
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SECTION I : I N T R O D U C T I O N 
1 HISTORICAL BACKGROUND 
Voltaire in his volume "Letters" (1733) refers to an 
ancient Chinese custom of inhaling the dried powder 
of smallpox crusts, rather like taking snuff to pre-
vent the development or recurrence of the disease. 
From practices such as these the rudiments of immuni-
ty to disease and the fundamentals of immunology as 
we know them today became estabiished, centuries be-
fore the concept of the germ theory of infectious 
disease. 
An important contribution and one which assured the 
future of immunology was made by Edward Jenner who 
published the results of his experiments in 1798 
after 20 years research in which he verified the 
belief that contact with cowpox afforded protection 
against smallpox. However, it was largely due to 
the research of Pasteur, the first great experimental 
immunologist, that preventive immunisation reached a 
high degree of sophistication with the development 
of living, heat-killed and attenuated vaccines. The 
term "vaccine" was coined by him in acknowledgement 
of the early work by Jenner in the field (Vacca, cow). 
Pasteur was also the pioneer in the germ theory of 
disease, and bacteriology as a science was born (1,2). 
Immunology developed along with bacteriology with the 
discovery of bacterial toxins by Roux and Yersin in 
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1888 and antitox ins b y Behr ing a n d Kitasa to in 1890 
(1). A major contribution was made by Buchner who 
was the chief advocate of the theory that body fluids 
contain a substance considered to be bactericidal 
which he termed alexine, and which we now know to be 
complement (1). The agglut ination test for bacteria 
is associated wi th the names o f von Gruber and Durham 
(3,4) while in 1896 Widal descr ibed the test for the 
diagnosis of typhoid fever (1). 
Towards the turn of the century the concept that the 
immune response depends on two distinct mechanisms, 
namely cellular (phagocytic theory) and humoral, 
emerged, the former attributable to Metchnikoff (1) 
and the latter to Ehrlich (5). At the time the close 
interrelationship between these two mechanisms was not 
fully appreciated and it was not until decades later 
that the importance of cellular irrnnunity was realised. 
Research in the field of humoral irrnnunity by contrast 
gathered mome~tum and it became increasingly clear 
that irrnnunology had implications far wider than the 
field of microbiology. 
With the elucidation of the mechanisms involved in 
anaphylaxis, the Arthus reaction and the allergic 
response, a new perspective was introduced in immuno-
logy (6) which was to have a profound effect on future 
thinking; namely that aberrations in the irrnnune re-
sponse may occur which are not only harmful, but which 
2 
may r e sult in the death of the host. 
The concept of "tolerance" a:'.'ld "self" versus "non-
self" was developed from Ehrlich's theory of "horror 
autotoxicus" by Burnet and Fenner in 1949 (7). This 
was followed by such discoveries as chimerism (8) 
and the clonal selection theory of Jerne (9) and 
Burnet (10) while in 1962 the central role of the 
thymus was established by Miller (11,12). At about 
the same time Porter (13) and Edelman (14) defined 
the structure and formation of gamma globulin . . 
Immunology has thus emerged as a multi-disciplinary 
science encompassing virtually all the fields of 
medicine and in particular the autoimmune diseases, 
cancer and organ transplantation. Furthermore in 
the past two decades there has been an upsurge of 
interest in a number of disorders in which a complex 
interrelationship appears to exist between the immune 
system and viral infections in genetically predisposed 
individuals. 
Systemic lupus erythematosus (SLE) is a prototype of 
such a disorder. The term "Lupus" derived from the 
Latin meaning "wolf" was coined at least seven centu-
ries ago and described any ·erythematous spreading 
ulceration of the face - a disease which eats away, 
bites and destroys. The earliest concept of lupus 
as a specific entity can be attributed to Cazenave 
3 
who in 1851, described a condition he termed "lupus 
erythemateux" and which almost certainly refers to 
d~scoid lupus. In 1872 Kaposi described acute and 
chronic forms of the disease and hinted at its sys-
temic nature. However it was largely due to Osler 
in his classic series of communications between 1895 
and 1904 (15,16) in which he described the wide 
clinical spectrum of SLE, that the systemic nature 
. 
of the disease was fully appreciated. He also pro-
posed an underlying vasculitis as a basis for the 
disease. 
The discovery by Hargraves (17) in 1948 of the lupus 
erythematosus (LE) cell phenomenon evoked much 
interest and generated the concept that SLE was an 
autoimmune disease. Another important milestone was 
reached when, from four centres, the occurrence of 
antibodies to DNA was reported (18). Since that time 
a large number of antibodies directed mainly to other 
nuclear and cytoplasmic constituents have been des-
cribed, and there is now ample evidence to support an 
immune complex basis for the disease. The etiological 
agent or agents however remain elusive and current 
research is being directed at the possible role of 
viral, immunologic, genetic and hormonal factors in 
the genesis of the disease, and also at further 
elucidating the resultant immunologic aberrations 
which occur. 
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2 THE DIAGNOSIS AND ASSESSMENT OF ACTIVITY IN SLE 
(i) CLINICAL 
In the majority of cases the diagnosis of SLE can 
be made clinically with reasonable confidence 
especially when the presentation is that of a 
multisystem disorder or when the organ involve-
ment is typical, such as a butterfly skin rash. 
The clinical spectrum is very wide and it is not 
the intention to discuss the presentations in de-
tail. There has been general agreement in the 
prevalence and spectrum of organ involvement in 
patients with SLE as borne out in the studies by 
Dubois (19,20,21), Harvey (22), Haserick (23) 
and Jessop and Meyers (24). 
Many of the features of SLE are not specific to 
the disease and may occur in a number of related 
and unrelated conditions such as other connective 
tissue disorders and viral or bacterial infec-
tions. In addition many cases of SLE may mas-
querade as idiopathic thrombocytopenic purpura, 
epilepsy, migraine, depression, idiopathic 
nephrotic syndrome, or seronegative arthritis 
(25). While the arthropathy of SLE is often of 
a relatively mild nature with little if any 
objective evidence of synovitis or deformity, 
severe involvement, indistinguishable from 
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rheumatoid arthritis (RA) may occur (26-28) and 
it is only ·by performing the appropriate sero-
logical tests that the diagnosis of SLE may be 
established. 
The diagnosis may also be complicated by the 
development in some patier.ts of syndromes in 
which features of two or more of the connective 
tissue disorders occur. A recent addition to 
this list of "overlap" syndromes is that of mixed 
connective tissue disease (MCTD), a term intro-
duced by Sharp (29) describing a syndrome com-
prising some of the features of SLE, systemic 
sclerosis (SS) and polymyositis. A number of 
reports further elucidating the disease have 
since appeared (30-35}. There is however a di-
vergence of opinion as to the validity of re-
garding MCTD as a distinct entity. Those in 
favour of the concept feel that the differentia-
tion from SLE is justified because in general 
terms patients with MCTD have a better response 
to corticosteriod therapy, tend not to develoF 
the systemic manifestations of SS, and renal 
involvement when it occurs is usually of a milder 
nature. 
(ii) ARA CRITERIA FOR THE CLASSIFICATION OF SLE 
The American Rheumatism Association (ARA) in 1971 
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published their preliminary criteria for the 
classification of SLE (36) based on a retrospec-
tive multicentr e analysis of 696 cases with 
SLE. Fourteen criteria were selected from 57 
features present in these patients. These are: 
facial erythema, chronic discoid lupus erythema-
tosus (CDLE), Raynaud's phenomenon, alopecia, 
photosensitivity, oral or nasal ulceration, non-
deforming arthritis, LE ceils (2 or more),false 
positive serological tests for syphilis, pro-
teinuria (> 3.Sg/day), cellular casts, pleurisy 
or pericarditis, psychosis or convulsions and 
haemolytic anaemia or leucopenia (<:4000/mm3 ) 
or thrombocytopenia (<:100,000/mm3 ). The 
presence of 4 or more or these criteria together, 
or developing subsequently were regarded as com-
patible with the diagnosis of SLE. While the 
usefulness of this classification has been estab-
lished in most epidemiological and clinical 
studies and in differentiating SLE from other 
connective tissue disorders such as RA (37-41),_ 
it excludes many with milder forms of the disease 
~ 
and those presenting with single organ involvement 
' 
without the necessary laboratory parameters to 
fulfil the criteria. A revision of the criteria 
is awaited and will almost certainly include the 
anti-DNA antibody (ADA) which has stood the test 
of time as the single most specific test cur-
rently available for the diagnosis of SLE. (See 
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pp 11-1 4. ) 
It is often possible by careful clinical evalua-
tion to assess disease activity. Thus the de-
velopment of a florid skin rash, polyarthritis, 
alopecia, constitutional symptoms or visceral 
involvement such as pericarditis indicate active 
disease. The clinical impression in most cases 
will dictate whether or not active therapy 
should be instituted. However, subclinical di-
sease activity undoubtedly does occur and when 
this involves an organ such as the kidney with 
its potentially poor prognosis, the problem has 
to be considered in conjunction with serological 
and other testing. Unfortunately, as will be dis-
cussed, none of the currently available immuno-
logical tests in isolation is sufficiently 
specific or reliable to either establish the 
presence of, or to predict the onset of an acute 
episode. 
(iii) LABORATORY 
a) LE Cell Phenomenon 
The discovery of the LE cell phenomenon by 
Hargraves in 1948 (18) was of great histori-
cal significance as the first diagnostic test 
for SLE. Not only could milder forms of the 
disease be recognised but it also paved the 
e 
way for further research in the field of 
antinuclear antibodies. While still per-
formed as a routine test in most laboratories, 
it is time consuming, lacks specificity and 
sensitivity and is not quantitative (42). 
It may be positive in a number of other 
conditions such as CDLE (43), Sjogren's 
syndrome (44), RA (45), and in chronic 
active hepatitis (46). · It is of no assis-
tance in the assessment of disease activity 
and its inclusion as one of the ARA classi-
fication criteria for SLE is likely to be 
reviewed. 
b) Antinuclear Antibodies 
The irnrnunofluorescence test for antinuclear 
antibody (ANA) is the standard screening test 
for SLE. It is semi-quantitative and is more 
sensitive that the LE cell test. However it 
also lacks specificity and a positive test for 
ANA (usually low titre) may be found in some 
patients with RA (47,48), SS (49), Sjogren's 
syndrome (50), ulcerative colitis (51), 
myasthenia gravis (52) and in burns (53,54) 
amongst others. It may also be found in 
relatives of patients with SLE (55) and in 
the elderly (56). However ANA in high titre 
is strong evidence in favour of SLE. Con-
versely a negative test usually but not 
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always excludes the diagnosis especially if 
active disease is present, and for some cases 
of cerebral lupus (57), late stage inactive 
lupus nephritis (58) and patients with 
lupus-like syndromes associated with comple-
ment component deficiency states (59}. 
Four major staining patterns of nuclear 
fluorescence are recognised (60). These 
patterns are not as specific for certain 
antibodies as previously thought although 
the rim pattern (also called ring, peripheral, 
membranous or shaggy) correlates well with 
ADA (61}. The homogenous pattern, due mainly 
to antibody to DNA-histone complex is frequent-
ly seen in SLE (62). The speckled pattern is 
due to antibody to saline-soluble nuclear 
components and is found in SLE, but recently 
a good correlation has been shown between 
this pattern, antibodies reacting specifi-
cally with ribonucleoprotein and MCTD (29}. 
The nucleolar pattern is seen most frequently 
in SS and in a proportion of patients with 
Sjogren 1 s syndrome (63). It is not uncommon 
to find mixed patterns in any one serum. 
The ANA test is therefore useful diagnosti-
cally but not as a parameter for monitoring 
disease activity. 
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c) Anti-DNA Antibodie s 
The Farr ammonium sulphate precipitation 
(64-66) and t he Ginsberg and Keiser millipore 
filter techniques (67) are sensitive and 
quantitative for the measurement of anti-
bodies to double-stranded DNA (dsADA). A 
good correlation between the two techniques 
has been demonstrated except at high levels 
of activity (67). Antibodies to DNA hav e 
been regarded for some years as the mainstay 
in the diagnosis of, and as a measure of 
activity in SLE because of their specificity 
( 6 8) • Antibodies to single-stranded DNA 
(ssADA) on the other hand lack specificity 
for SLE and occur in a number of other con-
ditions (69,70). 
Binding levels of more than 30% for dsDNA 
by the Farr technique or levels in excess of 
10 JJg DNA bound per ml serum by the Ginsberg 
and Keiser technique were considered vir-
tually diagnostic for SLE. 
Apart from its diagnostic value dsADA levels 
in general correlate well with disease acti-
vity (65,66,71-76). Thus binding levels of 
less than 30% (or less than 10 ).lg DNA bound 
per ml serum) are usually associated with 
inactive disease while higher levels, especial-
1 1 
ly if binding is greater than 70%, (or 
greater than 20 ).lg DNA bound per ml serum) 
strongly suggest active disease. Unfortunate-
ly this relationship is not absolute and it is 
not unusual to find that persistently high 
levels of dsADA may exist with little or no 
evidence of clinical activity (77-79). 
Nevertheless Lightfoot and Hughes (80) are 
of the opinion that in such cases severe 
exacerbations are more likely to occur 
eventually. It is also not possible to pre-
dict the nature of the acute attack which 
might follow rising levels of ADA. This 
poses a problem in treating on ADA levels 
alone, as corticosteroid or irnrnunosuppressive 
therapy are not necessarily indicated where 
the exacerbation takes the form of a mild 
flare of arthritis or skin lesions, whereas 
more aggressive treatment would be justified 
if active renal involvement ensued. 
It is well known that apart from antibodies 
which react exclusively with either dsDNA 
or ssDNA others, which crossreact with both 
dsDNA and ssDNA also exist. For this reason 
it was believed that in order to ensure the 
specificity of the assay for dsDNA (and 
therefore for SLE) care was necessary to 
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ensure that the DNA used in the assay was 
free of single-stranded regions. 
It has been shown however that it is tech-
nically difficult to prepare and to maintain 
preparations containing pure dsDNA (81,82). 
Even millipore filtration just prior to assay 
does not remove all single-stranded regions 
(83). In addition the assay method used to 
detect the antibodies may influence the 
results obta~ned. Claims of elevated dsADA 
occurring in some cases of Sjogren's syndrome 
(72), chronic active hepatitis (84), CDLE 
(85), uveitis (86) and RA (87) must therefore 
be viewed in the light of these observations 
(88) • 
In view of these difficulties the use of 
alternate forms of DNA has been proposed and 
include heat-denatured sonicated ssDNA of 
known molecular weight (89), a more stable . 
circular DNA (90) or synthetic dsDNA (91). 
The inconsistency between disease activity 
and ADA levels has raised a further possi-
bility namely that the pathogenicity of the 
ADA may be related to the qualitative proper-
ties of the ADA (namely the immunoglobulin 
class (92), the avidity (93,94) or the 
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precipitating or nonprecipitating ability 
(93) ) rather than the actual circulating 
levels. These properties are discussed 
in greater detail elsewhere. Another factor 
that must be considered is that if disease 
activity is associated with the formation 
and deposition of DNA-ADA immune complexes 
(IC's), then episodes of activity should be 
associated with decreasing rather than high 
or rising levels of ADA. Many autoantibodies 
other than ADA are found in SLE sera (95). 
It is therefore possible that additional 
non-ADA-containing IC systems may participate 
in the pathogenesis of the disease. 
d) Crithidia Luciliae Immunofluorescent 
Assay for dsADA 
This assay has been developed recently and is 
based on the detection of dsADA using the 
kinetoplast of the haemoflaggelate Crithidia 
luciliae which consists almost entirely of 
dsDNA (96-98). The assay is thus specific 
for dsADA, and the antibody class and titre 
can in addition be determined. It is, however, 
less sensitive than the Farr technique. 
e) · complement 
Many studies have demonstrated an association 
between complement depletion and clinical 
14 
disease acti vity, particularly when renal 
involvement is present (66,71,99-102). There 
is evidence that complement activation in 
SLE occurs by both the classical (103) and 
alternate (104) pathways and that fixation 
by the IC's of complement results in the 
development of hypocomplementaemia. While 
total haemolytic complement (CH50 ), c 1q, 
c3 and c4 may all be depressed at some stage, 
c4 levels are of particular value as they 
are the first to fall with activity and the 
last to return to normal levels with remis-
sion (101). Hypocomplementaemia and high 
levels of ADA imply smouldering, subclinical 
IC disease and are regarded by some as an 
indication for therapy (79). There is as 
yet no uniformity of opinion on this matter 
' 
since periods of hypocomplementaemia, some-
times of long duration, may revert to normal 
levels spontaneously without apparent clinical 
deterioration. A conservative approach to 
therapy, based on the clinical picture and 
guided by histology in the case of the kidney, 
rather than serologic abnormalities seems 
appropriate at present. 
f) Lymphocytotoxic Antibodies 
An overall prevalence of lymphocytotoxic 
antibodies (LCA) in up to 80% of patients 
15 
with SLE has been reported (105-107). In 
the study by Bortolotti and his colleagues 
(106) LCA were found in 100% of patients 
" 
with active disease and in 52% of those in 
remission. These antibodies are however not 
specific to SLE and have been reported in 
other connective tissue disorders, in viral 
infections such as infectious mononucleosis 
and measles, and in tuberculosis (reviewed 
by Dawkins et al (108) ) . 
LCA has also been documented in between 39% 
and 60% of consanguineous and nonconsangui-
neous relatives of patients with SLE, in 
their household contacts and amongst labora-
tory personnel handling ,SLE blood (105,107, 
109), as compared to a prevalence of 15% in 
normal subjects (107). 
Utsinger (110) found a correlation between 
lymphopenia and SLE in a study of 40 patients. 
Lyrnphopenia was greater during clinically 
active disease and showed a strong correla-
tion with LCA, hypocomplementaemia and ADA. 
Bortolotti (106) on the other hand found 
that lymphocytotoxins tend to persist in the 
circulation for several months after episodes 
of activity and he does not regard their 
presence as a suitable marker of activity. 
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Zvaifler and Bl uestein (111 ) were unable to 
demonstrate a corre lat ion between LCA in 
cryoprecipitates and ei t her the severity of 
SLE or the presence or absence of active 
lupus nephritis. 
Goldberg et al (112) made the interesting 
observation that LCA have specificity for 
the i antigen which is present on lympho-
cytes and cord erythrocytes. It is known 
that cold haemagglutinins with i specificity 
are capable of inducing haemolytic anaemia. 
Thus this crossreactivity between LCA and 
cord erythrocytes might explain the observa-
tion by Butler et al (113) that LCA are 
found more commonly and in greater titre in 
patients with haematologic abnormalities. 
Cerebral lupus is notoriously difficult to 
diagnose serologically. It is hoped that 
the suggested relationship between LCA and 
neurological involvement (113,114) will be 
borne out in further studies. 
The role of LCA in SLE has not been resolved. 
Family studies showing an association of LCA 
in patients with SLE, their relatives, 
including nonconsanguineous relatives and 
other household contacts suggest that an 
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environmental fac t or apart from genetic 
influences may be relevant to their develop-
men t. The p r a c tical value of determining 
LCA r emain s to be esta b li s hed. They appear 
to be too nonspecific to be of use diagnos-
tically and their value as a parameter of 
activity needs to be confirmed in further 
studies. Their role in the pathogenesis of 
the disease also requires further study. It 
is possible that they reflect an antiviral 
response and that by their action on cell 
membranes may lead to complement-mediated 
cell injury with the release of nuclear 
antigens (113). 
g) Extractable Nuclear Antigen 
Extractable nuclear antigen (ENA) is a mixture 
of soluble nuclear antigens, two of which 
have been well characterised namely ribonu-
cleoprotein (RNP) and a non-nucleic acid 
protein antigen (Sm) (115). The value of 
measuring these antigens in general terms 
lies not in the diagnosis of SLE or as an 
index of disease activity but rather to 
identify MCTD, a subset of SLE (29,116). 
h) Immune Complexes 
Measurement of circulating levels of IC's 
would appear to be the most rational approach 
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in the search of a marker of disease acti-
vity. A number of studies investigating 
this avenue have appeared in the literature 
recently with encouraging results (117-126). 
There are however a number of problems, 
methodological and other, which have to be 
solved before any meaningful conclusions 
can be drawn. 
pages 51-62 . 
These are discussed on 
. In summary, a number of immunological tests are 
available for the diagnosis of SLE. Some of 
these tests are also useful adjuncts in the 
assessment of disease activity. Recognising 
their limitations, investigations directed at the 
particular organ involved should always be carried 
out. In the case of the kidney assessment of 
renal function, the degree of proteinuria and the 
examination of the urinary sediment are still of 
major importance, while the decision of whether 
or not to treat depends almost entirely on the 
histological appearance (127,128). 
In cerebral lupus the problem of diagnosis and 
the assessment of activity are particularly 
thorny as there is very poor correlation between 
cerebral involvement and the usual monitors 
(129-132). Even serological changes in the 
cerebrospinal fluid have yielded conflicting 
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results. This may be due to t he fact that 
different pathogenetic mechanisms to the rest 
of the lupus syndrome are probably involved . 
Of interest t here f o re are two r e cent papers 
describing the prese nce of a n antineuronal 
IgG antibody in cerebral lupus (133,134). It 
is hoped that this will provide a new serologi-
cal guide in the diagnosis and assessment of 
activity in cerebral lupus: 
3 ETIOLOGY OF SLE 
A large body of clinical and experimental evidence 
is currently available which favours four major 
factors in the etiology of SLE. 
(i) GENETIC 
A genetic predisposition to the development of 
SLE is suggested by the higher prevalence of 
SLE itself, other connective tissue disorders 
and of "silent" serological abnormalities such 
as ANA, in close relatives of lupus patients 
(135-137). A few instances of SLE occurring 
in monozygous twins (138) and the development of 
lupus-like syndromes in subjects with inherited 
complement component deficiency states (59,139) 
have been documented. 
Early studies attempting to link SLE with specific 
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genetic markers of the huma n l e ucocy t e antigen 
(HLA) s y ste m have y i elded i nte r esting but dis-
cordant data. Nies et al (140) reported an 
increased incidence of HLA-A5 amongst black 
Americans with SLE while in other ser i es 
(141,142) an association between HLA-B8 and 
SLE was found. 
. 
It has r e cently been shown (143) that in fami-
lies with multiple cases of SLE, either HLA-A 
or -B haplotypes may be present in the individual 
family units. This suggests that a closely-
linked genetic factor rather than HLA-A or -B 
may be associated with the disease. 
Against this background the findings of the 7th 
International Histocompatibility Workshop in 
relation to the HLA-D region and SLE are of 
particular interest (144,145). HLA-DRw2 was 
present in 51% of patients with SLE and 26% of 
controls, while HLA-DRw3 was present in 49% of 
patients with SLE and 22% of controls - a striking 
increase of these antigens in SLE. No significant 
increase in HLA-A, -B or -c was found in 39 pa-
tients with SLE studied. In view of these fin-
dings it has been suggested that since HLA-B8 
and HLA-DRw3 are commonly co-inherited, the 
association between HLA~B8 and SLE i s apparent 
rather than real and that SLE should more cor-
21 
rectly be linked with HLA-DRw3. Further support 
for the importance of the HLA-D region as a gene-
tic marker in SLE has been derived from' family 
studies by the same group and also provide 
further evidence that co-inheritance of two or 
more genes in linkage disequilibrium with genes 
determining HLA-DRw2 or -DRw3 may be necessary 
for clinical disease to be expressed. 
It must however be pointed out that while these 
genetic markers may provide the soil for the 
development of SLE it is likely that additional 
genetic or environmental factors are necessary 
for full expression of clinical disease. 
The latter concept is illustrated in the study 
by Lowenstein and Rothfield (137) in which Ig, 
c3 , c4 and properdin deposits at the dermo-
epidermal junction were found in close contacts 
of patients with SLE, even in nonconsanguineous 
relatives, and in the study by De Horatius et 
al (109) of lymphocytotoxic antibodies. 
(ii) VIRAL 
A large volume of literature has accumulated over 
the last decade or more on the possible role of 
viruses in the etiology of SLE. While there is 
no firm evidence to implicate viruses either as 
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initiating or as perpetuatin g agents in the 
disease, several important contributions in 
the field have been made. 
It has been shown in animal studies that chronic 
viral infection can lead to immune complex 
disease while NZB/W F
1 
hybrid mice all of which 
carry a Gross type leukaemia virus develop an 
autoimmune disorder with many similarities to 
human SLE (146,147). The fact that the complexes 
in NZB/W mice are DNA-ADA in nature rather than 
viral antigen-containing suggests that additional 
factors, possibly genetic, are necessary for the 
development of autoimmunity. The discovery of a 
disease in dogs similar to human lupus, and 
transmissible by cell free extracts (148) further 
supports a viral etiology for SLE. 
Tubuloreticular and paramyxovirus-like structures 
have been demonstrated in the renal glomerular 
basement membrane of patients with SLE (149). 
It remains to be established whether these 
inclusion bodies represent viral material or 
whether they are products of chronic tissue 
damage, since similar inclusions have been demon-
strated in a number of other conditions and in 
normal subjects. These inclusions are however 
found more frequently and in greater quantities 
in SLE. 
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A number of studies hav e shown an increase in 
viral antibody titres in patients wi th SLE as 
compared to controls. These include antibodies 
~ 
to reovirus double-stranded ribonucleic acid 
(150), type C RNA (151), paramyxo (152), 
Ebstein Barr (153) and measles viruses (154-155). 
In another study antiviral antibody titres were 
significantly increased in relatives of patients 
with SLE when compared to controls (156). No 
association between hepatitis B virus and SLE 
was demonstrated in a study by Shorey et al 
(157). An interesting observation was made by 
Johanssen and colleagues (158) that while warts 
were shown to occur more commonly in a group of 
patients with SLE (25/26) than in a control group 
(19/160), wart virus antibodies were fourtd signi-
ficantly less often in patients with SLE. They 
postulate that some immune deficiency in the 
lupus subjects may account for these findings. 
It is not clear how to interpret . the relationship 
between SLE and viral antibodies from these studies. 
A direct causal relationship may be implied while 
on the other hand the increased incidence of 
these viral antibodies may simply be a reflection 
of the underlying immunological hyperreactivity 
common to many autoimmune diseases. No etiologi-
cal relationship between SLE and other infectious 
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agents, such as bacteria, has been established. 
(iii) ENDOCRINE 
There is a marked predilection of SLE and other 
connective tissue disorders for females. In 
adults the sex ratio is 9 females to 1 male (21) 
while the sex difference for prepubertal SLE is 
less striking being in the.order of 2-3 to 1 in 
favour of females (159). This association to-
gether with experimental evidence that females 
are more resistant to certain bacterial infec-
tions (160) led many investigators to study the 
effect of sex on the immune system. A large 
volume of data has accumulated confirming a pro-
found effect of sex on both humeral and cellular 
immunity and . on the development of autoimmunity. 
This data with particular reference to SLE will 
be reviewed. 
a) Humeral Immunity 
A hyperreactive humeral response based on 
antibody titres has been observed in females 
on exposure to E coli (161),brucella (162) 
and measles (163). In an earlier study 
immunoglobulin (Ig) levels and in particular 
IgM were found to be higher in females than 
in males (162), while family studies showed 
that the genes for IgM production are present 
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in the X chromosome (164). Higher levels of 
IgM have also been demonstrated in women on 
oral contraceptive agents (165) and in 
-~ 
younger rather than older women (162). 
Furthermore oestrogens administered to mice 
result in an augmented antibody response to 
sheep red blood cells (RBC's) (166) while 
females on dialysis who become infected 
with hepatitis B virus tend to develop 
antibodies to Hb Ag and become antigen-
s 
negative whereas males on dialysis tend 
to become chronic Hb Ag carriers (167). 
s 
b) Cellular Immunity 
Cellular imi~unity by contrast appears to 
be depressed in females compared to males. 
It has for example been shown in cytotoxicity 
studies that lymphocytes from normal females 
are half as effective as from males (168). 
Depressed phytohaemagglutinin-induced 
(PHA) lymphocyte transformation has also 
been demonstrated in females taking oral 
contraceptives (169), while oestrogen and 
progesterone have been shown to suppress 
the stimulatory effect of PHA and purified 
protein derivative (PPD) on human lympho-
cytes ( 170) . 
26 
c) Autoimmunity and SLE 
Not only is there a higher prevalenc~ in 
women of SLE and other connective tissue 
disorders, but also of a variety of auto-
antibodies (171). Acute attacks of SLE 
precipitated by oral contraceptive agents 
have been reported (172). Murine lupus, 
a disorder of NZB/NZW F
1 
mice which bears a 
close resemblance to the human counterpart 
runs a more aggressive course with earlier 
onset of glomerulonephritis, renal failure 
and death in female mice. In a number of 
experiments designed to alter the sex 
hormone status of both male and female 
mice either by castration or by the adminis-
tration of oestrogens or androgens to males 
and females respectively it was shown that 
severity of disease was related to the 
presence of oestrogens (173-175). It has 
not been established whether SLE is commoner 
in Klinefelter 1 s sydrome (176) but in a 
study on the hormonal status of two patients 
with the condition (177) augmented oestrogenic 
effects were shown~ It was suggested that 
this might influence the development of SLE 
in these individuals. 
There is thus ample evidence that females have 
hyperactive humeral immunity, depressed 
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cellular immunity a nd a greater predilect i on 
to the development of autoimmune disorders 
than males. 
(iv) IMMUNOLOGICAL 
The mechanisms responsible for the abnormalities 
of T and B cell function in SLE and the inter-
relationship between viral~ genetic and hormonal 
factors in bringing about these aberrations are 
incompletely understood. In two excellent 
recent reviews Steinberg (178) and Williams and 
Bankhurst (179) discuss the subject in the 
light of more recent developments. 
-
The absolute numbers of T and B cells are 
reduced in SLE especially during periods of 
disease activity (180). Anti-T cell antibodies 
may partly account for the reduced numbers of 
T cells. However, the major T cell abnormality 
in SLE appears to involve · specifically the 
suppressor T cells (181,182). The defect may 
not simply be a reduction in the generation of 
T cells but rather a defect in suppressor signal 
production. 
Since suppressor T cells are thought to play an 
important role in immunqlogic regulation and in 
the prevention of autoantibody production by 
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their effect on B lymphocytes, their absence or 
a defect in their ability to respond to B cell 
signals would result in uncontrolled prolifera-
.~ 
tion of B lymphocytes. 
There are many unanswered questions but from the 
evidence presented there is little doubt that 
genetic, viral and hormonal factors have a marked 
influence on the immune system in SLE. The end 
result is that of a semiautonomous situation of 
uncontrolled B cell proliferation, autoantibody 
production and a state of autoimmunity. 
4 EVIDENCE THAT SLE IS AN IMMUNE COMPLEX DISEASE 
There is considerable evidence that SLE is an IC dis-
order. This is derived from many detailed immuno-
fluorescence and ultrastructural studies of renal tis-
sue, analysis of glomerular eluates and from comple-
ment, antigen, antibody, and IC studies in serum. 
(i) THE KIDNEY 
The kidney is ideal for the study of SLE. Apart 
from the fact that biopsy material for sequential 
studies can be obtained with relative ease it has 
been shown by immunofluorescence studies that 
evidence of renal involvement in SLE can be found 
in almost 100% of cases (183). 
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a) Immunofluorescence 
Deposits localised along the glomeru~ar base-
ment membrane contain IgG, IgM, c1q, c3 , c4 
and DNA (184,185). The granular distribution 
of these deposits is typical of an IC disorder 
and while fine in the initial stages of the 
disease usually become coarser as the disease 
progresses (69). 
b) Electronmicroscopy 
Ultrastructural studies provide indirect 
evidence that these glomerular structures 
are IC in nature since they are electron 
dense and therefore unlikely to be fibrin 
(186,187). 
c) Acid Elution/DNase Digestion 
Acid elution and DNase digestion studies of 
glomerular material have isolated immuno-
globulins with antibody activity to ds- and 
ssDNA, ENA and nucleoprotein (188,189). 
Whether the presence of ssDNA in the eluates 
is merely due to denaturation of dsDNA after 
IC formation or whether de novo ssDNA com-
plexes are formed in the circulation has not 
been resolved. Koffler et al (190) believe 
that ssDNA IC 1 s are formed in the circulation 
and constitute a second important IC system 
in SLE. 
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(ii) THE BRAIN 
By contrast the role of the IC in the genesis of 
cerebr~l lupus is less clear. The lack of cor-
relation between the neurological manifestations 
and disease activity with the usual serological 
parameters, unless another organ is involved 
concomitantly, has led to the view that cerebral 
lupus is pathogenetically ~ distinct entity. 
There is however some evidence that IC deposition 
does occur. Atkins et al (191) demonstrated the 
presence of gamma globulin deposits in the choroid 
plexus of some patients with cerebral lupus. The 
staining pattern of these deposits diminished 
markedly after DNase digestion suggesting that the 
complexes involved were specifically DNA-ADA in 
nature. IgG deposits were demonstrated by Sher 
and Pertschuk (192) in the choroid plexus of a 
child with SLE and in NZB/W mice by Lambert and 
Oldstone (193). Carr et al (120) demonstrated 
DNA-ADA complexes in the serum and cerebrospinal 
fluid of a patient with lupus meningitis. Renal 
involvement in the absence of histological evi-
dence could not be entirely excluded in this case 
and, while of interest, no conclusions can be 
drawn from this single case report. 
It is hoped that the recently described association 
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between antineuronal a.nd lyrnphocytotoxic anti-
bodies with cerebral lupus will shed more light 
on its pathogenesis (113,114,133,134) . 
. (iii) THE SKIN 
While skin manifestations are common in SLE the 
histologic features in the majority of cases are 
nonspecific. 
Immunopathological studies similarly have failed 
to demonstrate any features specific to SLE, but 
have nevertheless provided evidence to support an 
IC basis for the lesions by the demonstration of 
Ig and complement deposition at the dermo-epider-
mal junction in 80-100% of patients (194-196). 
Of interest is the fact that similar deposits may 
be present in nonlesional skin particularly 
during periods of disease activity, in relatives 
(including spouses) of patients with SLE and in 
technicians handling lupus sera. Electron dense 
deposits similar to those seen in the glomeruli 
are present at the dermo-epidermal junction. 
Immune complex deposition has also been found in 
blood vessels (197) and in the spleen (198). 
(iv) SERUM 
Further evidence that SLE is an IC disorder is 
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derived from the fact that all the components of 
the IC can be demonstrated in the serum of most 
patients with SLE at some stage during the course 
of the disease. These include a variety of auto-
antibodies directed against nuclear and cyto-
plasmic constituents, notably antibodies to DNA 
and a reduction in serum total haemolytic comple-
ment and the c3 and c4 components of complement, 
especially during episodes of disease activity. 
It is also possible to detect soluble IC's and 
free DNA itself in the serum of patients with 
SLE. These are discussed in greater detail 
elsewhere. 
Interesting data has emerged from studies of 
cryoprecipitates found in about 35% of patients 
with SLE. Winfield et al (199) have shown that 
cryoprecipitates contain a high concentration of 
ADA with respect to that of the serum in SLE. 
Antibodies to ribonucleoprotein were also isolated 
from cryoprecipitates but less frequently and not 
in the concentrated form. c
1
q has been found in 
the precipitates and appears essential for cryo-
precipitation to occur. Thus cryoprecipitates 
provide a convenient source of antibody for the 
study of IC's in SLE. 
Davis et al (200) in a subsequent study confirmed 





the presence of significant quantities of DNA in 
cryoprecipitates. This latter observation how-
ever has not been borne out by other studies. 
In a recent review of the subject Lightfoot (201) 
makes the point that while the presence of IC's 
in lupus cryoprecipitates is not in dispute, the 
lack of demonstrable cryoproteinaemia in most 
patients with lupus nephritis raises some doubt 
as to their relevance in the pathogenesis of the 
disease. 
5 ANTI-DNA ANTIBODIES 
While little is known of the role of DNA-ADA complexes 
in SLE, numerous investigations suggest that the quali-
tative properties of the antibodies which participate 
in the formation of IC's are of considerable importance 
in determining the pathogenicity of complexes. 
(i) SPECIFICITY 
The clinical significance of ds- and ssADA and 
the role of these and other autoantibodies in IC 
formation has been discussed. 
(ii) IMMUNOGLOBULIN CLASS 
An association exists between the class of anti-









disease. IgG - 1 and IgG - 3 (185) the main 
complement fixing antibody classes tend to pro-
duce nephritis, while IgM antibodies which are 
not complement fixing do not. 
(iii) AVIDITY AND PRECIPITABILITY 
The interaction between antibody and antigen 
is of fundamental importan4e in the humeral 
immune response and has been intensively studied 
in SLE, particularly in relationship to the 
development of renal lesions. 
It was generally accepted that low avidity non-
precipitating antibodies are associated with the 
development of renal lupus due to their persis-
tence in the circulation, while high avidity 
precipitating antibodies are rapidly cleared in 
the form of complexes. Conflicting results, 
however, have been reported from various studies. 
Steward et al (202) found that non-precipitating 
low avidity antibodies were associated with 
glomerulonephritis in NZB/W mice and Kuriyama 
(203) related low avidity antibody to the develop-
ment of membranous and high avidity antibody to 
membranoproliferative lesions in rabbits. 
Koyama and his colleagues (204) found antibody 
35 
with higher avidity in the sera of a group of 
patients with active renal lupus than in those 
with inactive disease and in a group without 
nephritis. In those with high avidity antibody 
IC deposition was predominantly subendothelial 
and subepithelial in those with low avidity 
antibody. The latter findings are in agreement 
with a subsequent study of 10 female patients with 
-
SLE by Asano and Nakamoto (205). 
Transformation in renal lupus from one histologi-
cal pattern to another, although uncommon, is 
well documented (127,128). An interesting corre-
lation between histological transformation and 
changing antibody avidity w~s reported by Asano 
and Nakamoto (205). A patient with mesangial 
lupus nephritis with high avidity antibodies in 
the serum subsequently developed membranous 
changes preceded by the appearance of low avidity 
antibodies in the circulation. No relationship 
between antibody avidity and renal morphology 
was demonstrated in the study by Tron and Bach 
( 7 5) • 
However in two studies (93,206) an association 
between high rather than low avidity dsADA and 
the presence of lupus nephritis was shown, while 
in another study Winfield et al (94) were unable 
to show any difference in the avidity of ssADA in 
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patients with lupus nephritis or active SLE with-
out nephritis as opposed to patients with active 
nephritis. They postulate that the discrepant 
results in various studies may be due to the more 
rapid clearance from the circulation of high 
avidity antibody in the form of complexes. These 
may therefore escape detection while lower avidity 
antibodies which persist for longer periods are 
more easily detectable. Thus the reported asso-
ciation of low avidity antibody wit~ renal lupus 
may be apparent rather than real. 
The theory that lupus nephritis develops in the 
presence of non-precipitating antibodies must 
also be challenged following a report by 
Cameron et al (78) in which they found precipi-
tating antibodies in one third of sera from 53 
patients with lupus nephritis. Some of the 
patients with severe renal involvement showed 
the greatest precipitation. They concluded 
that the presence of precipitating antibodies 
does not necessarily protect against the develop-
ment of nephritis. 
A strong association between cutaneous vasculitis 
and the presence of precipitating antibodies is 
suggested since the latter were found in 11 out 
of 12 patients in two series (77,78). 
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Cameron suggests that avidity studies on material 
eluted from biopsies or from the kidneys of pa-
tients dying from nephritis . may clarify the 
question 6f antibody avidity and precipitability 
in SLE. 
6 DEOXYRIBONUCLEIC ACID 
(i) CIRCULATING DNA IN HEALTH ~ND DISEASE 
Circulating DNA has been reported in a wide 
variety of unrelated conditions such as SLE 
(207-211), RA (208,210,211,212), malignancy 
(207,211), liver disease (207,213) and in infec-
tive endocarditis, pulmonary embolism and after 
surgery (213). In addition elevated levels have 
also been reported after cardiac surgery involving 
periods of extracorporeal circulation (213), after 
haemodialysis (214)~in patients on high dose corti-
costeroid therapy (215) and in response to the 
injection of bacterial lipopolysaccharides (216). 
In some of the above conditions ~tis claimed 
that the levels of circulating DNA found are 
pathologically elevated; however, there is a 
wide divergence of opinion as to what constitutes 
the normal levels of circulating DNA, levels 
ranging from less than 50 ng/ml to as high as 
13,8 ~g/ml having been reported (207,208,210-213, 
217-219). 
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Confirmation of elevated levels of circulating 
DNA in pathological states therefore requires 
resolution of this problem of the normal range. 
This wide variation in reported levels is 
probably due to lack of specificity in the assay 
method, and also depends on whether the assay is 
performed on plasma or serum (213,219,220). 
Davis and Davis (213) showed that DNA may be re-
. 
leased into serum during the process of coagula-
tion or during separation of the clot from the 
serum. Similarly Steinman (219) in comparing 
four assays for the measurement of DNA in plasma 
and serum found that DNA was undetectable in 
plasma while a mean level of 1,9 ~g/ml was detec-
table in serum. On the basis of these findings 
it was concluded that serum is unsuitable for the 
determination of circulating DNA levels. 
(ii) SOURCE OF DNA 
It has been suggested that while the DNA may be 
of exogenous (for example viral) origin (221-223) 
in the majority of cases it is probably of endo-
genous origin from tissue injury (traumatic or 
inflanunatory) and as such represents a nonspecific 
phenomenon (207,209,215) 
It is interesting to speculate on the role of 
leucocytes as a source of DNA in the circulation. 
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It is well .known that their turnover is increased 
in pathological states such as inflammation or 
injury, but in addition a number of "physiologi-
cal" factors are responsible for the normal 
diurnal variation in the leucocyte count (224). 
These include physical and emotional stress, 
pregnancy and exposure to sunlight. These factors 
may also precipitate acute attacks of SLE. It is 
possible that this phenomenon may be related to 
the increased turnover of leucocytes during 
episodes of physiological (or other) leucocytosis 
with the release of increased quantities of DNA 
into the circulation of patients with SLE,with 
IC formation. Whatever the source of the DNA, 
in SLE patients with circulating ADA, the pre-
sence of DNA in the circulation provides an 
opportunity for IC formation. 
(iii) ANTIGENICITY OF DNA 
The relevance of circulating DNA has been a sub-
ject of much debate particularly with regard to 
its possible role in immune complex formation in 
SLE. 
Why DNA should become antigenic in patients with 
SLE is unexplained. It is possible that anti-
bodies produced to viral nucleic acids merely 
crossreact with human DNA since it has been shown 
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that ADA in lupus sera will crossreact with DNA 
from many sources (225). 
Alternatively interference with DNA breakdown 
may render it immunogenic. It has for example 
been shown that in 50 % of patients with ANA a 
heat-liable inhibitor to deoxyribonuclease 
(DNase) is present (226). 
ssDNA on the other hand is a more potent irnrnuno-
gen than dsDNA. Levine et al (227) found that 
rabbits immunised with ultraviolet-irradiated 
(UV) DNA produced antibodies to unaltered purines 
and pyrimidines and to thymine dimers. The 
irnrnunogenicity of UV-irradiated DNA was confirmed 
by Tan (228) in a subsequent study. 
It has also been shown that thymine dimers are 
resistant to DNase digestion (229). It is also 
possible to induce thymine dimer formation in 
the cell nuclei of skin (230), and in a most 
interesting experiment Natali and Tan (231) 
having induced high circulating levels of anti-
bodies to thymine dimers in mice, subjected them 
to whole body UV-irradiation. Skin biopsies taken 
subsequently revealed changes virtually identical 
to those at the dermo-epidermal junction of human 
SLE. 
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There is also some evidence that irradiated DNA 
induces the formation of antibodies, usually of 
low titre, which crossreact with dsDNA (230,232). 
The important fact which emerges from these and 
other experiments is that the UV spectrum pro-
ducing alterations in DNA structure with increased 
antigenicity encompasses the sunburn wavelength. 
The relevance of this finding is important in 
relation to SLE where exposure to sunlight may 
in some cases precipitate acute attacks, and 
needs to be further explored. 
(iv) CLEARANCE OF DNA FROM THE CIRCULATION 
Natali and Tan (233) showed that the clearance of 
UV-irradiated and native 3HDNA administered 
intravenously to normal rabbits was similar in 
that less than 10% of the radiolabel was detec-
table after 60 minutes. After the injection of 
large amounts of UV-DNA to hyperimmunised rabbits 
some radioactivity was still detectable after 60 
minutes. No comparison however was made of the 
disappearance characteristics of the two forms 
of DNA in these animals. 
Tsumita and Iwonga (234) showed that DNA is 
rapidly cleared from the circulation due mainly 
to. excretion by the kidney but that a small amount 
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is trapped in the liver. 
In another study (235) a more rapid clearance of 
nucleic acids (dsDNA, ssDNA and poly I-C) was 
demonstrated in mice with circulating antibodies 
than in those without. In addition uptake by the 
liver and spleen was noted. 
Barnett (236) demonstrated that most of an 
administered dose of 125 I ss- or dsDNA to normal 
and immunised rabbits was cleared by approximately 
10 minutes but that the clearance was somewhat 
slower in the immunised rabbits. In addition 
there were also qualitative differences in the 
clearance of ss- and dsDNA. A secondary rise of 
radioactivity in the circulation was shown which 
was attributed to the release of DNA which had 
been taken up by some area of the body. Autopsy 
studies of the animals showed that this uptake 
was confined to the liver and spleen. 
These studies therefore indicate that DNA is 
rapidly cleared from the circulation by renal 
excretion but that some is trapped, at least 
temporarily, in the liver and spleen. A diffe-
rence in clearance rates of nucleic acids from 
normal and immunised animals has also been demon-
strated. The difference in clearance in ss-
versus dsDNA may indicate immunogenicity of the 
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former and non-imrnuno ge!"licity o f the latter. 
(v) METHODS FOR THE DETECTION OF CIRCULATI NG DNA 
'l'hese include: 
1 The Diphenylamine reaction (237,238) 
2 Immune prec i pitation by double diffusion 
in agarose (239) 
3 Complement fixation (208) 
4 Fluorimetry using ethidiurn bromide (217) 
5 Counterirnrnunoelectrophoresis (CIE) (213) 
6 RNA-DNA hybridisation (220) 
7 Radioirnrnunoassay (RIA) ( 211 , 21 8) 
Some of these assays, such as complement fixation 
are indirect measurements of DNA. Furthermore 
many of the assays lack either specificity or 
sensitivity or both. Thus nonspecific protein 
binding (218) or the presence in biological 
fluids of substances which interfere with assays 
based on colorimetry or fluorimetry, such as 
serum chromogens in the diphenylamine method 
have resulted in falsely high DNA values. In 
most cases the sensitivity of these assays is 
limited to the~g range. The RIA and modified 
CIE techniques are currently the most sensitive 
methods, the lower limit of detection being 
about 50 ng/ml of circulating dsDNA. Immunologi-
cal methods such as these, while sensitive have 
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the disadvantage that only sterically unhin-
dered antigenic sites are detected, so that 
in crude nucleoprotein preparations only 1% 
to 5% of the total DNA may be measured (240). 
The RNA-DNA hybridisation assay overcomes this 
problem and in addition provides information 
about the base sequence (and therefore the 
origin) of the DNA assayed. Steinman, 
however, notes that the high specificity of 
this technique may impose limitations on its 
usefulness in that it may not be applicable 
where the base sequence of the DNA is unknown. 
It is therefore useful where a qualitative 
and highly specific assay of DNA is required 
but, due to its complexity is unsuitable as 
a routine laboratory procedure. 
7 THE IMMUNE COMPLEX 
While dsDNA-ADA complexes are virtually exclusive 
to SLE the likelihood that ssDNA-ADA and other IC 
systems also participate in the pathogenesis of 
the disease has been alluded to. Apart from the 
antigen responsible for the formation of the IC, 
other factors including the properties of the IC 
formed, their rate of clearance from the circula-
tion and various tissue factors are equally if 
not more important in the initiation of tissue 
damage. 
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(i) SITE OF FOR..~TION 
The fundamental issue of whether immune com-
plexes are formed primarily in the circulation 
and subsequently filtered out in tissues or 
whether de novo formation in tissues occurs 
has not been fully resolved. The fact that 
soluble IC's can be measured in serum suggests 
that intravascular formati~n occurs. On the 
other hand a number of interesting observations 
have been made to support the theory that local 
formation of immune complexes also occurs. 
Izui et al (241,242) recently demonstrated that 
free DNA binds readily to collagen in the 
glomerular basement membrane raising the possi-
bility that DNA binding may occur locally as a 
primary event followed by antibody deposition 
and IC formation. They showed in addition that 
ssDNA has a greater affinity for collagen than 
dsDNA so that complexes of the former tend to 
occur locally while the latter forms complexes 
predominantly in the circulation. Should this 
hypothesis be correct it follows that the nature 
of the circulating DNA is of importance. Davis 
et al (200) in a discussion on the mechanisms 
in DNA-ADA mediated nephritis in SLE suggest 
that in a situation of antigenic excess DNA 
readily binds to collagen. Should an anamnestic 
response ensue ADA becomes bound to DNA with 
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resultant local IC formation in tissues. Alter-
natively where elevated levels of circul~ting 
ADA already exist, intravascular formation of 
IC's occurs followed by secondary entrapment 
along the glomerular basement membrane or by 
clearance from the circulation by the reticulo-
endothelial system (RES). 
It is likely therefore from the available evi-
dence that both intravascular and local forma-
tion of IC's occur. The extent to which intra-
vascular formation occurs and the nature of the 
immune complex formed are of importance in 
determining the therapeutic efficacy of 
manoeuvres such as plasmaphoresis or extra-
corporeal circulation (243). These forms of 
treatment would theoretically only be rational 
if significant intravascular formation of 
immune complexes occurs, unless tissue-bound 
complexes are released into the circulation. 
(ii) SIZE 
The size of an IC is dependant on the nature 
and properties of its constituent antigen and 
antibody and also on the relative concentration 
of antigen to antibody. Thus complexes are 
generally larger at eq~ivalence,that is, where 
an equal number of antigen and antibody mole-
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cules are present in the circulat i on at the time 
of IC formation. The valency of the antigen and 
antibody will also determine the size of the IC, 
the higher the valency, the larger the complex 
formed. If the antibody is rendered univalent 
by enzyme digestion, or if the antigen intrinsi-
cally contains a small number of determinants, or 
is relatively tolerogenic, smaller complexes will 
result (201). 
There is evidence to suggest that the size of 
the IC has clinical relevance. It has for 
example been shown in mice and in humans that 
small IgG complexes ie 1-1.Sx10 6 daltons are 
frequently associated with lupus nephritis 
while larger complexes, 2.5-5.0x10 6 daltons, 
as might occur if only IgM is present do not 
produce renal disease (244). 
It is important to appreciate in studies of this 
nature that most IC assays .are capable of detec-
ting large more readily than smaller complexes 
(245). Thus failure to detect IC 1 s in patients 
with SLE does not necessarily imply their absence. 
The importance of the size of IC 1 s in determining 




The RES and mononuclear phagocytic systems serve 
an important function in eliminating IC's from 
the circulation (246). The facility with which 
this occurs depends not only on the integrity of 
the RES (which may be ineffective due to "fatigue" 
(247), ageing (248) or a genetic factor (249) ) 
but also on the nature of the IC to be cleared. 
Large complexes are more efficiently eliminated 
from the circulation by the RES than smaller 
complexes. Smaller complexes thus tend to remain 
in the circulation for longer periods of time and 
are more liable to be deposited in tissues and to 
produce tissue injury. 
A recent contribution by Miller and Nussenzweig 
(250) proposes a role for c3b and possibly c4b 
in splitting membrane-bound IC's. This is thought 
to occur via the alternate pathway by the inser-
tion of these components into the antigen-antibody 
lattice resulting in the formation and release of 
smaller complexes. The biological properties of 
these solubilised complexes are altered in such 
a way that they have a lower binding affinity 
for platelet and leucocyte membranes. As a result 
they are less likely to mediate an inflammatory 
response through the release of vasoactive amines 
and lysosomal enzymes from these cells. Further 
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evidence for the role of complement in solubili-
sing membrane-bound complexes is derived from 
studies which demonstrate a delayed clearance of 
complexes from the glomeruli of hypocomplemen-
taemic rabbits with acute serum sickness (251). 
(iv) TISSUE FACTORS 
The vessel wall acts as a fjlter which retains 
large complexes and allows smaller complexes to 
pass through. This is especially true of the · 
glomerulus which may be regarded as a sieve for 
molecules of varying sizes (252). Depending 
on the severity of the glomerular involvement 
the characteristics of the sieve may be altered, 
but in general terms relatively large complexes 
are trapped in the mesangial and subendothelial 
areas, intermediate complexes in the glomerular 
basement membrane and small complexes under the 
epithelial foot processes. It has also been 
postulated that the mesangium may be the initial 
site for IC deposition and that overflow along 
the glomerular basement membrane occurs only 
after this barrier becomes saturated. 
The situation regarding DNA-ADA complexes in 
SLE has by no means been resolved and is due 
in part to the paucity of studies investigating 
specifically their role in the disease. This 
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again can be attributed to the lack of a current-
ly available sensitive method for the detection 
of these specific complexes. 
(v) IMMUNE COMPLEX MEASUREMENT 
As a result of interest in the possible clinical 
significance of circulating IC's a large number 
of techniques are currently available for their 
detection (245,253,254). The methods are based 
on the physical or chemical properties of the 
IC and vary markedly in their specificity, sensi-
tivity and reproducibility. Some assays serve 
merely as screening tests for the presence of 
IC's while others are unsuitable for routine 
clinical use due to their complexity and are 
reserved as research tools. 
IC assays may be subdivided according to those 
which detect specific complexes, that is, where 
the antigen is known, and those which detect 
the presence of non-specific circulating IC's. 
a) Antigen Specific Techniques 
Since it is likely that a multiplicity of 
antigen-antibody systems may be involved in 
the formation of IC's, methods which detect 
specific IC's have a limited application in 
the routine investigation of a suspected IC 
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disorder, but have the decided advantage of 
permitting study in individual disorders, 
such as SLE. 
Detection of Specific IC's include:-
1 Electronmicroscopy 
Direct visualisation by electron micros-
copy has been used to detect aggregated 
particles of HBs-antigen within IC 1 s in 
patients with HBs-antigen associated 
infective hepatitis (255). 
2 Physico-chemical 
These include: 
2.1. the detection of neuroblastoma-
specific IC's by radio-counter-
electrophoresis (256). 
2.2. measurement of the actual complex-
bound-antigen as opposed to the 
free antigen, by measuring the 
amount of the former removed from 
the circulation after specific 
precipitation or absorption of the 
host Ig's (257). 
2.3. Harbeck et al (117) claim to detect 
specific DNA-ADA IC's by demonstra-
ting an increase in free ADA titres 
following ·removal of DNA from the 
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r 
IC's by DNase I digestion. This 
phenomenon could not be reproduced 
by others. 
There are, therefore, very few 
methods available for measuring 
specific IC's and of particular 
relevance to this study is the 
lack at the present time of a 
generally accepted assay for the 
detection of DNA-ADA re's in SLE. 
b) Antigen Nonspecific Techniques 
1 Tests based on the Physical Properties 
The physical properties of an IC differ 
from those of the free antibody and anti-
gen which constitute it. These differen-
ces include an increase in molecular size 
and alterations in the surface properties, 
solubility and electric charge. Based on 
these principles a number of assays for 
IC's have been developed. These include 
ultracentrifugation (258), gel filtration 
(259) and affinity chromatography (260). 
As a group they lack specificity and are 
not suitable for routine use. Polyethy-
lene glycol (PEG) precipitation which can 
be used to separate IC's and aggregated 
IgG from monometric IgG may provide a 
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simple screening t e st (261). 
2 Tests Based on Biological Properties 
The majority of the tests currently in 
use are based on the biological proper-
ties of IC's. These assays depend on the 
recognition by the IC of either certain 
humoral factors or cellular receptors. 
2.1. Humeral Factors 
The humoral factors on which these 
assays are based include binding of 
the IC to:-
2.1.1. the first component of C' 
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(c1 , notably c1q} which trig-
gers activation of the com-
plement system (262). Measure-
ment of the anticomplementary 
activity (263} has the dis-
advantage of poor inter-assay 
reproducibility and is diffi-
cult to quantitate. The 
test is positive in the majo-
rity of patients with active 
SLE and also in many patients 
with RA. The c1q d~viation 
(264) and c1q latex aggluti-
nation (265} assays are limi-
ted by their high sensitivi-
ty to substances other than 
IC material, a problem not 
encountered to the same ex-






q solid phase 
(267) assays. The c
1
q 
binding assay is positive 
in a significant proportion 
of SLE and RA sera. The 
c
1
q solid phase assay is 
claimed to improve sensi-
tivity. 
2.1.2. antiglobulins, such as 
rheumatoid factor. These 
include the RF agarose 
precipitation test, radio 
assays using insolubilised 
monoclonal RF or soluble 
polyclonal RF, or inhibi-
tion of latex agglutination 
by RF (268,269). In these 
assays the presence of 
rheumatoid factor in the 
test sample may interfere 
with the assay. 
2.2. Cellular Receptors 
A number of functional assays have 
been devised which utilise the 
principle that the IC will interact 
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with cells bearing on their surface 
receptors for the Fe fragment and 
c
3
b of the complex (270,271). 
These assays depend on the integ-
rity of the cells used and may con-
sequently be influenced by the pre-
sence of cytotoxic factors or by 
rheumatoid factor, in the test 
samples. These assays include 
the platelet aggregation test, 
inhibition of antibody-dependent 
cell-mediated cytotoxicity and the 
Raji cell radioirnrnune assay, inhi-
bition of complement-dependent 
lymphocyte rosette formation 
(272-274). 
c) Cryoprecipitates 
Cryoprecipitates occur in a variety of diseases 
and have been shown to contain IC material 
(275). Cryoprecipitates when present in the 
sera of patients with RA appear to be a re-
liable marker for certain extra-articular 
manifestations of the disease (276). 
Cryoprecipitates are also found in SLE and 
provide a useful source of IC in a concen-
trated form for study. 
IC's have been measured by these assays in a 
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wide variety of clinical and experimental 
situations. It is perhaps not surprising 
that in many instances there has been a lack 
of correlation between the various assays 
employed and the disease studied, when one 
considers the widely differing principles 
on which the assays are based. It is also 
likely that few assays will detect the same 
IC. Studies attempting to relate the IC to 
disease activity thus have to be viewed with 
caution unless a nu.~ber of methods are em-
ployed. 
Most if not all current IC assays fall short 
of the ideal. The aim should be to develop 
an assay which is sensitive, relatively 
specific but with a wide spectrum of activity 
for IC's, reproducible, relatively simple to 
allow for standardisation and it should not 
require heat inactivation or a particular 
absorption of the sample before testing. 
d) Problem of Specificity 
One of the major problems is the inability of 
many assays to differentiate nonspecifically 
aggregated Ig's from true IC's. The problem 
is magnified by any procedure which generates 
nonspecific aggregates such as repeated 
freezing and thawing, or heating of samples 
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at more than 56° before testing. Adequate 
control experiments should also be performed 
in the evaluation of any assay to detect the 
~ 
presence of substances which may interfere 
with IC determination (245). 
These measures include: 
1 The determination of the size of the 
material detected since IC's are larger 
than mohometric Ig's. 
2 The use of manipulations which alter the 
size and/or biological properties of IC's 
such as fractionation in well-defined 
physicochemical conditions and reduction-
alkylation. 
3 Confirmation that the test becomes nega-
tive after removal of Ig's from the tested 
sample by immunoabsorption. 
4 Treatment with DNase to exclude inter-
ference with DNA. 
5 Testing in the presence of EDTA to ex-
clude the interference of C-reactive 
protein. 
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6 The determination of the various classes 
and subclasses of Ig's present in the 
IC. This is relevant to the specificity 
of those assays which are based on the 
biological properties of the IC. 
Until these aims have been achieved the com-
bined use of a number of assays will be 
-necessary in evaluation of IC disorders. 
Bruneau et al (121) compared three assays 
(C 1q precipitation, anticomplementary activity 
and DNase treatment) in 38 patients with SLE 
over periods of up to 4 years. Their observa-
tions were correlated with ~linical activity 
(especially proteinuria) and other laboratory 
parameters (ADA and complement levels). Of the 
three methods measurement of the anticomplemen-
tary activity was found to be the most useful 
clinically. 
More recently (1978) a WHO Collaborative Study 
(277) was undertaken in which 18 tests were 
compared in a number of diseases known to be 
associated with circulating IC 1 s, including 
idiopathic inflammatory disorders, SLE, RA, 
nephritis, vasculitis, tropical diseases 


















Six of the a s says fulfilled most of the criteria 
for the ideal complex assay. These were .c 1q 
binding, c
1
q solid phase, conglutinin binding, 
Raji cell test, monoclonal RF inhibition and 
platelet aggregation tests. 
The sensitivity of the 6 assays was comparable 
and none require heat inactivation or absorption. 
The Raji cell and conglutinin binding assays 
were the most sensitive for aggregated Ig's. 
Most of the assays were found to be specific 
for IC's containing IgG antibodies except for 
c
1
q binding assay which also detects IC's 
containing IgM. 
The remaining twelve assays tested were consider-
ed suitable only for a particular laboratory in-
vestigation. 
While different results were obtained in the 
various disease states investigated by these 
methods, a certain pattern of reactivity 
corresponding to each of the groups of diseases 
was noted, suggesting differences in the biolo-
gical reactivities of IC's. This point may 
be illustrated from their data showing that 
higher levels of IC's were present in RA 







monoclonar RF assays , while the inverse was true 
with Raji cel~platelet aggregation and ~
1
q 
solid phase assays. 
It therefore seems likely that the apparent 
discrepancies in IC levels using various methods 
are due to differences in the constitution and 
biological properties of the IC, according to 
the clinical s i tuation. 
In SUi'llffiary therefore: 
1 A large number of methods are currently 
available for the detection of !C's. 
2 Most of the assays are antigen-nonspecific 
and are based on the physical or biological 
properties of the IC. 
3 The various assays detect different com-
plex material and it is therefore advisable 
to employ a number of assays when evaluating 
IC disorders. 
4 Inter-laboratory standardisation allows 
·for more meaningful comparative studies. 
5 There is a need to develop more antigen-
specific IC assays, for example, DNA-ADA 
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assays in SLE. 
8 THE IMMUNE COMPLEX, COMPLEMENT AND TISSUE INJURY 
SLE is regarded as a Type III hypersensitivity (278) 
autoimmune IC disorder in which circulating IC's de-
posited in affected organs initiate a sequence of 
events which leads to tissue damage. It bears a 
strong resemblance to experimental serum sickness 
(279-281) where the appearance of arteritis and 
nephritis coincide with the rapid clearance of 
antigen as antigen-antibody complexes are formed. 
Deposition of these IC's in target organs results 
in tissue damage from activation of the complement 
system and neutrophils (von Pirquet 1911). 
Under normal circumstances IC 1 s are rapidly cleared 
from the circulation. If, however, there is a con-
stant source of antigen or if the clearance mecha-
nisms are ineffective (pp 49-50) the IC may persist 
in the circulation and become trapped in vessel walls. 
In rabbits IC deposition is facilitated by an increase 
in vascular permeability from two mechanisms (280), 
namely, the release of platelet aggregating factor 
from sensitised basophils, and from the release of 
stored histamine from platelets by their interaction 
with IC's. Whether these reactions occur in the 
human situation remain to be established. In addition 
it is likely that hydrodynamic physical forces also 
aid in the localisation of complexes in vessel walls. 
This stems from a study by Fisher and Bark (282) 
who showed that IC deposition was more intense in 
hypertensive animals where the transmural filtra-
tion pressure is high. 
In the kidney there are additional mechanisms which 
favour the deposition of IC's. These include c3b . 
receptors (283) and an affinity for DNA of the 
glomerular basement membrane (241,242~ a filtering 
action in the kidney for trapping IC 1 s (252) referred 
to earlier. 
The IC itself does not cause tissue injury, but once 
localised, it initiates the process by activating the 
complement system. This is achieved by the incorpo-
ration of the c
1
q subunit of c
1 
to a specific binding 
site on the antibody of the complex, namely the CH2 
area of the Fe fragment (284). The results of com-
plement activation are twofold. Firstly, the IC 
becomes more soluble due to incorporation in the 
antigen-antibody lattice of c3b, derived mainly 
from the alternate pathway and thought to facilitate 
the subsequent clearance of ·IC 1 s by the RES. Secondly, 
and of far greater importance is the generation and 
release of various pharmacologically active byproducts. 
c3a, c5a and the intermediate complex C567 are media-
tors in the inflammatory response by virtue of their 
strong chemotactic properties (285). Neutrophils 
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and other cells (macrophages, mast cells, B lympho-
cytes and platelets) thus accumulate in and around 
IC 1 s. These cells have on their surface receptors 
for both the Fe portion of the IC and for c3b. The 
IC's become attached to the cells, a process known 
as immune adherence (281) and may be regarded as the 
end result of chemotaxis. I roJUune adherence is usually 
followed by phagocytosis of the IC during which time 
a number of hydrolytic and other active materials are 
released. These compounds include a number of pro-
teolytic enzymes capable of hydrolysing collagen, 
elastin and basement membranes and further amplify 
the inflammatory reaction by an action on the pros-
taglandin, clotting and fibrinolytic systems. In 
addition c3a and c5a have anaphylatoxic properties 
which release histamine from mast cells and platelets 
(286). 
The end result is tissue damage which encompasses 
singly or in combination a nu.~ber of pathological 
changes such as acute or chronic inflammation, 
enzymic degradation of connective tissue and necrosis. 
r 
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SECTION II : D E O X Y R I B O N U C L E I C 
A C I D 
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MATERIALS AND METHODS 
1 Chemicals 
Acrylamide and N, N-methylene bisacrylamide (British 
Drug Houses, Poole, U.K.) were recrystalised as 
described by Loening (287). Ribonucleate 
3'-pyrimidino-oligonucleotidohydrolase (RNase), 
EC No 2.7.7.16, and deoxyribonu~leate 5'-oligo-
nucleotidohydrolase (DNase), EC No 3.1.4.5., were 
chromatographically purified preparations (Miles 
Laboratories, Indiana). Methyl 3H-thymidine and 
125r · d d . d. h d f R d. -10 o eoxyuri 1ne were pure ase ram a 10-
chemical Centre, Amersham, and ethidium bromide 
from Sigma Chemical Company. 
All other reagents were of Analar or equivalent 
quality. 
2 DNA Extraction 
Blood was collected into 10 ml heparinised Vacutainer 
tubes (Becton-Dickinson, Rutherford, New Jersey) and 
centrifuged within 4 hours of collection at 3000 rpm 
in a Sorvall RC-3 centrifuge at 15°C. Plasma was 
removed carefully, leaving a clear 1 ml (equivalent 
to about 7 mm) above the cell layer. The plasma was 
then again centrifuged at 3000 rpm for 10 minutes and 
the top 3 ml of plasma again 'pipetted off taking care 





and any pelleted material. The plasma was stored at 
this stage by freezing at -15°C. DNA was extracted 
from 1.5 ml plasma by mixing with an equal volume 
of phenol saturated with water. Water-saturated 
chloroform, 1.5 ml, containing 1% (v/v) isoamyl-
alcohol was then added. After vortex mixing for 
40 seconds the two phases were separated by centri-
fugation for 15 minutes at 6000 rpm and 4°C in the 
SS-34 rotor of a Sorvall RC-2B centrifuge. After 
a further extraction with chloroform, nucleic acids 
in 1.0 ml of the aqueous phase were precipitated by 
the addition of 2 ml of absolute ethanol, and after 
standing at -15°C overnight, centrifuged for 30 
minutes at 10 000 rpm and 0°C in the SS-34 Sorvall 
rotor. The . tubes were inverted and left to drain 
until almost dry. The precipitated nucleic acids 
were dissolved in 120 ...ul of electrophoresis buffer 
containing 5% v/v glycerol (layering buffer). 
Preparation of DNA Standards 
DNA was prepared essentially as described previously 
(288). The DAB-1 line of rat hepatoma cells, ob-
tained from Dr C Albrecht, was used for its capacity 
of growing to high c~ll densities in monolayer 
' 
culture, thereby giving a high yield of DNA, and 
because of its good uptake of labelled pyrimidine 
I 
nucleosides (289). DNA was also prepared on occasions 
·from the CCL2 line of HeLa cells and from E.coli K12. 
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Cells were propogated in 75 cm
2 
Falcon Flasks in 
Eagles minimal essential medium supplemented wtth 
10% foetal calf serum (GIBCO) and in the presence . 
of antibiotics. Cultures were monitored for myco-
plasma contamination as described previously (290). 
Cells were labelled just before reaching confluence with 
2 ;.1Ci/ml methyl 3H-thymidine or 1 ).lCi/ml 
125
I-iodo-
deoxyuridine for 1 hour at 37°C. The medium was then 
decanted and the monolayer washed once with 5 ml 
saline. 
The monolayer was dissolved by the addition of 3 ml 
1% sodium dodecyl sulphate in 1 M sodium perchlorate, 
pH 7.4, and incubated for 30 minutes at 37°C. The 
viscous lysate was mixed using a rotomixer with an 
equal volume of chloroform containing 1% isoamylalcohol 
and saturated with 1 M sodium perchlorate and the 
phases separated by centrifugation at 2500 rpm for 
10 minutes. The aqueous phase was removed and extracted 
twice more with chloroform reagent or until clear. 
DNA was precipitated by the addition of 2 volumes of · 
ethanol. The DNA was then dissolved in 0.1 x saline 
sodium citrate (SS~), made up to standard strength SSC 
(0.15 M NaCl and 0.015 M trisodium citrate pH 7.0) and 
treated with RNase, 1 pg/ml for 30 minutes at 37°C fol-
lowed by a further incubation with 10 pg/ml Pronase for 
30 minutes at 37°C. After two further extractions 
with the chloroform reagent, DNA was precipitated from 










0.1 M Tris-HCl, pH 7.5 and 10 M EDTA to give a stock 
solution of about 200 pg/ml. 
stored at -15°C until use. 
This was aliquo~ed and 
To prepare a working preparation of DNA the stock was 
diluted with 0.01 M Tris-HCl, 0.13 M NaCl pH 7.5 to 
about twice the final working concentration and fil-
tered through a 0.45 )lIIl millipore filter. The 
concentration was checked by measuring the radio-
activity in an aliquot, the specific activity having 
been previously determined. Additional Tris buffer 
was then added to bring the working concentration of 
DNA to 10 µg/ml. The DNA was sheared to a constant 
size by rotomixing at full speed for 30 seconds. 
Typical specific activities for 3ij-DNA were 30 000 
cpm/µg and 20 000 cpm/µg for 125 r-DNA. Three or 
four standard concentrations were prepared by serial 
dilution of this DNA in electrophoresis buffer 
containing 5% glycerol so as to contain between 12.5 
and 250 ng of DNA in the 100 ~l aliquots to be applied 
to the gel. 
Polyacrylamide Gel Electrophoresis 
This was performed in Tris-phosphate EDTA buffer 
essentially as described previously (291). An 
electrophoresis apparatus was designed to hold 20 
cylindrical perspex tubes (4 x 84 mm) into which the 
gels were cast. A concentration of 3.6% acrylamide 
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was prepared by dilution from a stock 12 % (w/v) 
acrylamide solution containing 0.3 % (w/v) N, 
N'-methylene bisacrylamide (2.5 % crosslinked). The 
gels were stored at 4°C for 18 hours before use. 
After the gels were cleared of any residual poly-
merisation products by passing current fo~ 30 
minutes at 100V, 100 pl of the test samples and 
the standards were layered on arrlelectrophoresed for 
2 hours at 100 volts. The gels were extruded into 
electrophoresis buffer containing 0.5 ~g/ml ethidium 
bromide and left overnight to equilibrate with the 
stain. 
5 Quantitation of Fluorescence and Calculation of 
DNA Concentration 
Fluorescent bands were quantitated with a Vitatron 
TLD 100 fluorescent scanner and integrator using 
UVB excitation and UV4 emission filters. The 
aperture was a 0.25 mm spot. A calibration curve 
was drawn using the three standard DNA concentra-
tions and the quantity of DNA in each unknown read 
off this linear plot. Plasma DNA could be quanti-
tated in this way at levels of 10 ng/ml or greater. 
A typical calibration curveT and an electropherogram 
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DNA concentration (ng/ml) 
(a) A typical fluorimetric scan of plasma DNA elec-
trophoresed in a 3.6% polyacrylamide gel; direc-
tion of electrophoresis is from left to right. 
(b) Calibration curve constructed from four different 
concentrations of a standard rat hepatoma DNA 
preparation electrophoresed in polyacrylarnide 
gels and scanned as illustrated in (a) quanti-
tating the band with an electronic integrator. 
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RESULTS 
1 Specificity of the Assay fords-DNA 
The staining and mobility characteristics of various 
preparations of DNA electrophoresed in polyacrylamide 
gels, are illustrated in the upper panel, Fig. 2. 
The standard rat hepatoma DNA preparation shows a 
single well defined fluorescent ~and on the gel. An 
extract from a human plasma sample shows a fluorescent 
band migrating with similar mobility to the standard 
and, except for minor quantities of fluorescence at 
the top of the gel, no other bands are visible. The 
disappearance of this band after DNase treatment, and 
its persistence after RNase treatment, confirm that 
the band seen in plasma extracts is DNA. After 
heat denaturation, fluorescent material is only 
demonstrable as a diffuse smear in the top few mm 
of the gel. 
The slope of a plot of electrophoretic mobility 
versus gel concentration is characterist~c for 
different classes of nucleic acid structure, namely 
single-stranded, double-stranded linear, and double-
stranded circular (291). Plots of this type are 
illustrated in Fig. 2, lower panel, for the plasma 
DNA and the standard DNA. Quadratic equations were 
fitted to the two data sets and standard deviations 
on the quadratic coefficients were determined. 
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Statistical evaluation of the two sets using the t 
test, showed that they arise from the same po~ulation, 
(p > 95%). This confirms that the structure and 
conformation of the fluorescing material in the band 
is double-stranded linear DNA of molecular weight 
6 greater than about 5 x 10. 
1 2 3 4 5 6 7 8 9 10 
2·0 3·0 4·0 
Acrylamide concentration % 
FIG. 2 
Upper Panel: PAGE for 2h at lOOv of 100 ng standard 
rat hepatoma DNA (1) or of nucleic acid preparations 
from either plasma (2,4-10) or serum (3) from one 
individual, the serum and plasma samples being taken 
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at the same time. (2) Untreated plasma extract. 
(4) Plasma treated with 30 pg/ml DNase for 60 min 
at 37°prior to extraction. (5) Plasma treated 
with 10 pg/ml RNase for 30 min at 37° prior to ex-
tragtion. (6) Plasma extract heated for 5 min at 
100 followed by rapid cooling. (7-10) Plasma 
extract electrophoresed on 2.1, 2.7, 3.3 and 4.0% 
polyacrylamide gels respectively. 
Lower Panel: Gel concentration range analysis of 
0----0, plasma nucleic acid extract, and o ~~ •, 
rat hepatoma DNA. Samples were run at the same time 
on 2.1, 2.7, 3.3 and 4.0% gels (plasma samples 
illustrated in upper panel 7-10). The distance 
migrated was determined from scans of the gels, 
correcting for differential stretching (hence the 
migration values do not correspond exactly with the 
photographed gels). Quadratic functions were 
fitted to the two data sets by the method of least 
squares. 
Nature and Collection of Blood Samples 
The effect on plasma DNA concentrations of using 
different gauge needles was tested by drawing blood 
into heparinised syringes with either a 19 or a 25 
gauge needle, and into a heparinised Vacutainer 
tube with a 21 gauge needle. The sample taken 
through the 25 gauge needle was traumatised by 
forcibly expressing the blood through the needle 
several times to the point of red cell lysis. The sample 
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analysed in duplicate by the Vacutainer method gave 
a mean DNA level of 56 ng/ml (S.D. ~ 3 ng/ml)w~ich 
was not significantly different (p:>0.1) to the 
level produced using the heparinised syringe with a 
19 gauge needle (63 ~ 4 ng/ml). However, DNA levels 
were significantly higher in the traumatised sample 
(126 ~ 33 ng/ml, p C::::::0.02) inferring that damage to 
leucocytes can release DNA into the plasma. 
Two centrifugation steps were found to be necessary 
to remove all cells from the plasma sample. Cyto-
centrifugation (Cytospin, Shandon Elliot), and using 
May-Grundwald and Giemsa stains, confirmed that no 
cellular material could be detected in plasma subjected 
to the standard 2 cycles of centr~fugation, whereas 
leucocytes were still visible after only one centri-
fugation. 
The effect of residual cells on DNA levels, by measuring 
DNA in the top 2 ml of plasma after a single cycle 
of centrifugation and compared with DNA levels in the 
2 ml below this, leaving 1 ml of plasma undisturbed 
above the huffy layer is shown in Fig. 3. The top 
layer of plasma gave a mean value of 114 + 75 ng 
DNA/ml, whereas the lower 2 ml gave a value of 





























DNA levels in the lower 2 ml plasma after a single 
cycle of centrifugation are represented by the open 
blocks and in the upper 2 ml plasma by the hatched 
blocks. 
Stability of DNA in Stored Samples 
Selecting a patient with a relatively high concentra-
tion of plasma DNA, levels were measured in freshly 
separated plasma and, over a period of 24 hours, in 
plasma samples stored at 37°c, 20°c, 4°c and -20°c. 
(Table I). Similarly samples stored at -20°c were 














No significant change in DNA concentration was 
demonstrated under any of the storage conditions 
described. 
TABLE I 
Effect on plasma DNA levels of incubation of plasma 
at various temperatures, 
Figures give plasma DNA in ng/ml (mean of duplicate 
measurements+ 1 S.D.) 
Duration of incubation (h) 
1 3 6 24 
Plasma incubated at 93+4 96+8 123+21 111+12 
37°c 
Plasma incubated at 102+2 57+21 96+ 8 
20°c 
Plasma incubated at 90+25 
4°c 
Plasma incubated at 86+ 6 
-20°C 
Recovery 
DNA was added in 25,50,250 and 500 ng quantities per 
ml to aliquots of plasma having levels of endogenous 
DNA less than 10 ng/ml. The samples were then 
extracted and analysed in duplicate (Table II). The 
results show that the percentage recovery is in 
excess of 80% for 50 ng or more but falls appreciably 
to less than 60% for 25 ng added. Serum treated in 













Only a slight diffuse fluorescence was noted in the 
top first cm of the gels (compare with Fig. 2, Gel 3). 
TABLE II 















The within-group variability of plasma DNA levels 
performed in duplicate on 42 samples showed a standard 
deviation of 13,8%. This degree of variability was 
maintained down to levels of about 40 µg/ml plasma. 
Plasma Versus Serum 
In 11 subjects DNA levels were measured in both plasma 
and serum drawn at the same time. In 5 subjects 
clearly defined DNA bands were visible in the gels of 
the plasma samples but not in the gels of the equiva-
lent serum samples. Instead, only a diffuse fluores-
cence in the top 1 cm of the gels similar to that seen 
for DNA added to serum was visible. The appearance 
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of 3 of these paired plasma and serum samples is 
illustrated in Fig. 4. No DNA was detectable in 
either plasma or serum from the remaining 6 subjects. 
The diffuse fluorescence precluded accurate quanti-
tation; consequently all DNA determinations were 






The staining characteristics of 3 representative 
paired plasma and serum samples extracted and 
analysed for DNA. The well-defined bands in the 
plasma gels (P) and the lack of discernible 
bands in the serum (S) gels are shown. 
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Because of the marked difference between DNA levels 
in heparinised plasma and serum, DNA was assayed 
in plasma using both heparin and EDTA as anti-
coagulants, and compared to levels in serum. The 
plasma levels were the same irrespective of whether 
heparin of EDTA was used while the marked dis-
crepancy between plasma and serum levels was 
again noted. This data excludes the possibi-
lity that heparin itself could account for this 
difference. 
Normal Range of Plasma DNA 
Plasma DNA was measured in 58 normal subjects 
(Fig. 5) comprising 29 males and 29 females 
aged 15 to 68 years (mean 34 years). In 47 
subjects (81%) DNA levels were <:: 10 ng/ml. 
In the remaining 11 subjects levels ranged from 
10 to 54 ng/ml. There was no significant 

































Distribution of plasma DNA levels in active and 
inactive SLE (differentiation made on clinical 
criteria), in patients immediately on termination 
of 6 hours of haemodialysis, and in controls, the 
latter consisting of normal blood donors, not 
matched for age or sex. 
Physiological Variation in DNA Levels 
The effect on circulating DNA levels of exposure 
to the sunburn spectrum of UV light was tested 
in two normal Caucasian volunteers, a male and 
a female aged 33 and 34 years respectively, as 
follows: the minimal erythema dose (HED) was 
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established for each subject (292) whereupon a 
whole body exposure of 4 MED was administered 
to each using a Theraktin sunlamp fitted with 
a TL/1240 W fluorescent tube with a spectrum 
peaking at 306 nm. Blood was drawn before 
and 6, 24, 48 and 72 hours after exposure for 
DNA assays and differential white cell estima-
tions. No DNA was detected in any of the 
. 
samples. While the total leucocyte counts in 
the subjects remained unchanged, both developed 
a relative lymphocytosis 48 and 72 hours after 
· exposure. (224). 
Five blood samples were drawn from each of 4 
male and 4 female subjects aged 15-68 years 
(mean 37 years) over a 24 hour period and assayed 
for DNA. Plasma DNA levels remained undetectable 
(less than 10 ng/ml) in all the subjects through-
out the 24 hours while all demonstrated fluctua-
tions in the white cell count consistent with 
the normal diurnal variation. 
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1500 1900 2300 h 
Leucocyte and DNA levels measured in a subject over 
24 hours. DNA remained undetectable throughout 
while the wide fluctuations in the leucocyte count, 
consistent with the normal diurnal variation, 
occurred. 
Plasma DNA in Pathological Conditions 
Plasma DNA levels were measured in 47 patients all of 
whom fulfilled the preliminary ARA criteria for the 
classification of SLE (36-41). One hundred and seven 
assays were performed over a period of 8 months. The 
majority had levels below 10 ng/ml and in the few cases 
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where higher levels were recorded no association could 
be established with respect to the type of organ in-
volvement (Table III) nor were there significant differ-
ences in levels between clinically active and quiescent 
phases of the disease or between SLE as a group and a 
normal control group (Fig 5). Since high levels of 
circulating DNA have been reported after haemodialysis 
(214), plasma DNA levels were also measure in 4 patients 
with chronic renal failure (not associated with SLE) 
immediately on termination of 6 hours of haemodialysis. 
Two were found to have considerably elevated levels 
(Fig 5) • 
TABLE III 
Breakdown of plasma DNA levels in SLE with respect to 
the predominant organ or system involved at the time 
of measurement. 
No. of samples with levels 
<10 ng/ml >10 ng/ml Total 
1 Clinically active 
(organ or system) 
Skin 7 1 8 
Musculo-skeletal System 18 2 20 
Kidney 5 0 5 
Nervous System 3 0 3 
Cardiovascular System 0 1 1 
Non-specific (constitu- 5 1 6 
tional symptoms) 
.. . . . . 
11 Clinically inactive 53 1 1 64 
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DNA DISCUSSION 
The specificity of this physico-chemical assay for dsDNA 
was established by a number of features: 
The extraction procedure with phenol and chloroform quanti-
tatively removes proteins, lipids and low molecular weight 
compounds soluble in 70% alcohol. Polysaccharides are the 
only components which regul arly contaminate nucleic acids 
extracted in this way. Their presence, however, does not 
affect the assay since their mobility characteristics on 
acrylamide gels are very different to those of polynucleo-
tides. Furthermore, polysaccharides do not fluoresce 
when stained with ethidium bromide. 
Ethidium bromide is cnacrydine dye which fluoresces when 
bound to polynucleotide chains of 4 nucleotides or more 
(293). The fluorescence produced by ethidium bromide is 
due to its ability to intercalate into a double helix and as 
such it is specific for double-stranded polynucleotides 
although a lesser degree of fluorescence is given by 
single-stranded species. 
Nucleic acids have well-defined electrophoretic mobility 
characteristics in polyacrylamide gels, which are dependent 
on size, strandedness (i.e. double or single), conformation 
{i.e. circularity or linearity of the molecule), and nature 
of the ribose sugar (i.e. DNA or RNA) (291,294).. A useful 
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feature of the gel electrophoresis method is that the 
electrophoretic mobility .of dsDNA is virtually independent 
of molecular weight above a value of about Sx10
6 
daltons 
( 291) . This property is also shown by dsRNA although its 
electrophoretic mobility at higher molecular weight values 
is lower than that of DNA (294) and is therefore readily 
distinguishable by comparison with DNA markers. Single-
stranded polynucleotides may electrophorese either faster 
or slower than high molecular weight dsDNA depending both 
on their size and on acrylarnide concentration (291), and 
can be distinguished from dsDNA by this latter property and 
by the less well defined bands which they form. The slope 
of the plot of electrophoretic mobility for the polynucleo-
tides present in the test sample at different gel concen-
trations was statistically similar to that of a standard 
DNA preparation (Fig 2). In these studies the variable 
presence of s~allquantities of ill-defined fluorescence 
near the top of. tlegel represented the only evidence for 
single-stranded er extensively denatured species detectable 
by this method in plasma. 
The lack of a discernible band after DNase treatment of plasma 
and its persistence after RNase treatment provide further 
evidence that the band which fluoresces with ethidiurn bromide 
is DNA and not RNA. 
Thus the combination of the selective extraction procedures 
and the demonstration of a single band on gel electrophoresis 
























sensitivity, and electrophoretic mobility at different 
acrylamide concentrations confirm unequivocally that we 
are quantitating native dsDNA. 
Since heparin is a highly-charged molecule the possibility 
that it might·in some way account for the tliscrepancy between 
plasma and serum DNA levels was considered. 




There was no difference in DNA levels whether heparin or 
EDTA was used as an anticoagulant. 
The staining and mobility characteristics of the test 
DNA are identical to those of the standards, which have 
never been in contact with heparin. 
3 Since heparin does not fluoresce with ethidiurr. bromide 
the chances of it augmenting _the fluorescence attribu-
table to ethidium bromide binding to DNA are remote. 
This is further supported by the fact that in the recovery 
experiment the quantity of DNA recovered from the samples 
did not approach or exceed 100% of that added before 
the extraction procedure . 
It is not known why plasma containing DNA produces a well-
defined band on gels whereas serum fails to do so. A hypo-
thesis which would at least partly explain the absence of a 











It has been shown that while both plasma and serum contain 
DNase, levels are considerably higher in serum (226). This 
is thought to be due to the release of DNase during clotting 
from platelets which contain DNase in a high concentration 
relative to plasma (295). It has also been shown that serum 
nucleases are capable of destroying nucleic acids (296,297). 
Since nuclease activity would create fragments which migrate 
faster than dsDNA, the DNA would be sufficiently degraded to 
account for the diffuse fluorescence occasionally seen in 
the region of, or just below the expected dsDNA migration. 
This would also explain the absence of a visible band when 
DNA is added to serum. Since no definitive bands were 
visible in this region it was not possible to either quanti-
tate or to determine the nature of the polynucleotides 
present in the fluorescent blush. 
The hypothesis would not explain the fluorescence in the top 
1 cm of the gel since fluorescence in this region implies 
that the DNA is in a denatured rather than a degraded form. 
Davis and Davis (213) showed that DNA is sporadically released 
during clotting an<l therefore considered serum unsuitable for 
the assay of DNA. It would be interesting to know whether 
the DNA they refer to is predominantly single-stranded, 
double-stranded, or partially degraded. 
From the appearance on the gel it would appear that in serum 
some DNA is partially denatured, some is partially degraded 






















in sufficient amounts to be accurate ly quantita t ed and the 
study was confined to dsDNA in plasma. To what ex~ent the 
serum findings are artifactual due to the clotting process 
rather than representing the in vivo situatioh requires 
further study. 
The marked effect of contaminating l eucocytes in plasma on 
DNA levels must be emphasised. Due to inadequate plasma 
separation in the preliminary stages of this study a wide 
range of DNA levels was found in normal subjects and in a 
variety of disease states. Levels as high as 1000 ng/ml 
were recorded in normal subjects and it appeared in addition 
that there was a marked diurnal variation of DNA levels • 
The reason for these wide fluctuations became clear only 
after a series of experiments were performed to test the 
adequacy of sample collection and plasma separation. 
DNA levels recorded for blood drawn atraurr.atically and by 
the vacutainer method were similar and exclude the possibility 
that either the vacuum or the needle in the latter traumatise 
leucocytes to any significant degree. Thus DNA levels 
measured on blood drawn by the vacutainer method reflect 
true circulating plasma DNA. This is of importance as we 
confirmed the findins of Tan et al (207) that sufficient 
trauma to cells can significantly alter DNA levels. 
Of even greater importance are the steps that must be taken 
to ensure that the plasma is cell-free. Since one human 













~ 4 . 1 contamination level o~ only 10 cells/ml p asma to give a 
DNA level of 60 ng/ml. It is therefore necessary to remove 
greater than 99.9% of leucocytes from the plasma before 
assay. This is especially relevant when an extraction 
procedure which disrupts cell membranes prior to assay is 
used. The high levels of DNA and the presence of cells 
in the lower 2 ml compared to the significantly lower DNA 
levels and the absence of cells in the top 2 ml plasma 
after a single cycle of centrifugation emphasise the care 
that must be taken to avoid cellular contamination. For 
this reason 2 centrifugations were performed routinely 
leaving 1 ml plasma undisturbed above the cellular layer 
after each centrifugation. From a 10 ml sample of blood 
sufficient plasma was obtained (about 3 ml) to perform all 
assays in duplicate. Tan et al (207), recognising the need 
for serum free from contamination with cellular breakdown 
products, used the method of Gupta and Herriot (226) for 
the collection of their samples. 
Levels of plasma DNA found in normal subjects were considerably 
lower than those of some reported series (210, 211, 217), 
but similar to those reported by others (207, 212, 213, 219). 
It is most unlikely that this can be explained by differences 
in the selection of normal subjects and the reasons are 
presumably methodological since the various techniques are 
based on widel'l differing principles. No comment can be 
made on the effect on DNA levels of contaminating leucocytes 
in those assays not requiring&~ extraction procedure, since 
this aspect was not investigated in the study. 
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DNA appears to be stat le in plasr,1a. 
0 Even at 37 Cover a 
24 hour period, and over a 4 week period at -20°c t~ere 
is no significant change in DNA concentration. ~his data 
together with the fact that there was no difference in DNA 
levels in samples assayed immediately on plasma freshly 
separated at 20°c compareQ to samples stored at -15°c 
excludes the possibility that DNA is precipitated in tDe cold 
(such as in the form of cryoprecipitates) to any significant 
degree. Furthermore it is likely that the concentration of 
DNase in carefully collected plasma is too low to materially 
affect DNA levels, even after prolonged storage. Finally 
the presence of DNase inhibitors in plasma may interfere with 
any DNase whicD might be present. (226,298,299) 
The recovery studies demonstrate that DNA in plasma can be 
mea-sured accurately at levels of 50 ng/ml and abovei below 
50 ng/ml recovery falls appreciably. The results obtained 
for 250 ng and for 500 ng ad~ed to plasma are similar to 
those of Cox and Gokcen (211) using a RIA technique. The 
assay is reproducible even at levels as low as 40 ng/ml 
and compares favourably with that of Leon et al (218), also 
using a RIA method. 
Since no diurnal. fluctuations in DNA were recorded in any of 
the 8 subjects studied, it must be concluded that no diurnal 
variation exists and that the release of endogenous DNA into 
the circulation is not influenced by any of the normal acti-
vities of daily living experienced by the subjects, such as 
eating, sleeping, exposure to moderate physical or emotional 
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stress, or by the "physiological'' variation of leucocytes 
which was demonstrated in all the subjects. Should variations 
in DNA indeed occur they are too small i.e. less than about 
10 to 20 ng/ml to be detected by this assay. 
No effect on circulating DNA levels was recorded in the 
small series of two subjects exposed to sunburn irradiation. 
The dose administered was sufficient to cause substantial 
erythema and lymphocytosis, yet avoided blistering or 
necrosis which could conceivably affect DNA levels. For 
ethical reasons patients with SLE were not included in this 
series. It would be interesting to compare DNA, ADA, CH50 
and IC levels in those patients who develop an exacerbation 
of the disease following sun exposure with those who do not. 
Raised plasma DNA levels were not observed in the group of 
patients with SLE. In no instance could a relationship 
between DNA levels and involvement of a particular organ 
be demonstrated, nor did plasma DNA levels vary with disease 
activity. These findings are in conflict with other 
studies (207-211). In some of these reports it is possible 
to find an alternative explanation for DNA elevation. 
Tan et al (207), for example, detected DNA in 11 of 95 patients 
with SLE. It is interesting to note that in 2 of the patients 
who had multiple assays performed the appearance of DNA in 
the serum coincided with the commencement of high dose 
corticosteroid therapy, and disappeared from the circulation 
as therapy was reduced, an association described by Hughes 
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et al (215). The presence of DNA in the serum of these 
patients can therefore not necessarily be ascribed to 
\ 
disease activity itself. No reference was made to the 
therapy administered to the remaining nine patients. 
Koffler et al (210) found elevated levels of ssDNA in the 
serum from 13 of 18 patients with SLE tested randomly. 
Marked elevations of ssDNA were found in some patients with 
SLE followed serially when compared to other conditions. 
In addition antibodies to ssDNA were found throughout most 
of the clinical course. They suggested that ssDNA has a 
special significance in the pathogenesis of the disease. 
Unfortunately they were unable to det~rmine dsDNA directly 
due to insufficient quantities of antisera with specificity 
for dsDNA. Their data which emphasises the role of ssDNA 
in SLE therefore cannot be compared to that of our study 
where specifically dsDNA is quantitated. 
Another study worthy of comment is that of Cox and Gokcen 
(211). Serum DNA levels (comprising total, ss- and dsDNA) 
were measured in normal subjects and in a variety of disorders 
by a RIA technique requiring phenol extraction and using dog 
serum as a source of DNA-binding protein. Nine patients with 
SLE were studied. The mean serum DNA concentration in these 
individuals was twice that of the normal range while marked 
fluctuations were demonstrated in individual subjects investi-
gated serially, many levels being within the normal range. 
Reference however was not made to the number of assays perfor-
med on these patients or whether the fluctuating levels bore 
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any relationship to disease activity. dsDNA was undetec table 
in 2 patients, and in the group as a whole accounted for only 
16% (about 116 ng/ml) of the total circulating DNA. They 
postulate that the low levels of dsDNA relative to ssDNA in 
patients with SLE may be due to the elimination of dsDNA 
from the circulation in the form of dsDNA-ADA IC's. This is 
in accordance with our experience of low dsDNA levels in 
SLE apart from the fact that the actual levels recorded 
by them are higher than in our study. 
An association between cerebral lupus and systemic vasculitis, 
and the presence of circulating dsDNA has recently been 
demonstrated (300). Confirmation of Steinman's findings 
would be of interest since the evidence for a DNA-IC-mediated 
pathogenesis in cerebral lupus is scant¥· It would be vital 
in ·such a study to exclude the coexistence of other organ 
involvement (such as the kidney) by all available means and 
to monitor not only dsDNA, but also dsADA and DNA-IC serially 
in these patients. 
A number of aspects pertaining to the assay technique and 
patient selection must be considered before data from various 
studies can be compared and conclusions drawn. 
These may be summarised as follows: 
1 Whether plasma or serum is used. 
2 The precautions taken to ensure that the samples tested 
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are free of cellular material parti6ularly when an 
extraction procedure with phenol and/or chloroform is 
used. 
3 The speci£icity of the assay for DNA 
4 Whether single-stranded, double-stranded or total 
DNA is measured. 
5 Whether the assay is reproducible and shows a good 
percentage recovery. 
6 The exclusion of other factors which may account for 
elevated DNA levels, such as corticosteroid therapy. 
7 Whether levels are measured during active or inactive 
phases of the disease. 
Evidence has been presented that our assay fulfils all the 
criteria for the assay of dsDNA and the requirements for 
the assay have been clearly stated. 
From the data presented it is postulated that two alternative 
explanations may account for the low circulating levels of 
dsDNA in patients with SLE. 
1 The release of dsDNA into the circulation of patients 
with SLE is no different to that found in normal subjects 
and perhaps ssDNA or DNA is a slightly altered form not 
95 
detectable by our technique are of more importance 
in the pathogenesis of the disease. 
2 Alternatively dsDNA is an important immunogen in SLE 
and the low circulating levels are due to the fact 
that any DNA released into the circulation is mopped 
up by ADA and eliminated in the form of complexes. 
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SECTION III: THE DNA 
COMPLEX 
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I M M U N E 
A S S A Y 
MATERIALS AND METHODS 
1 Chemicals 
2 
Deoxyribonucleate 5'-oligonucleotidohydrolase, EC No 
3.1.4.5., and the Bgl II, Hind III, and Eco R 1 
restriction endonucleases and the wild type lambda 
DNA were purchased from Miles Laboratories, Indiana. 
Methyl 3H-thymidine and 2- 14c-th~midine were purchased 
from Radiochemical Centre, Amersham and Dimilume-30 
scintillation mixture from Packard. 
All other reagents were of Analar or equivalent 
quality. 
DNA Irr~une Complex Assay 
To 0.5 ml of serum, heat inactivated for 60 mins at 
56°c, is added 4.5 ml of 0.01 M Tris-HCl, 0.13 M NaCl, 
' 
pH 7.5. The diluted sera are then passed under a 
pressure difference of 15kPa through 0.45 um pore 
size 25 mm diameter cellulose nitrate membrane filters 
(Millipore Corp., Bedford) which are then washed x 3 . 
with 5 ml Tris-HCl buffer to remove any free ADA from 
the filter. This step reduces nonspecific binding 
to the filter to a minimum. The filter is then cut 
accurately into two equal halves. To one half is 
added 0.5 ml 0.15 M Tris-HCl, pH 7.5 and to the other 
half 0.5 ml b.15 M Tris-HCl, 0.003 M MgC1 2 , pH 7.5, 
containing 50 pg pancreatic DNase. After incubation 
at 37°c for 3 hours 0.05 ml 0.5 M EDTA, 0.15 M Tris-HCl, 
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pH 7.5, 0.03 M MgC1 2 , containing 50 ~g DNase was 
added to the first half filter, and 0.05 ml 0.5 M EDTA, 
0.15 M Tris-HCl, was added to the second half filter 
to stop the reaction. A blank containing 0.5 ml 0.01 
M Tris-HCl, 0.13 M NaCl, pH 7.5, handled in the same 
way as the serum samples was included with each assay. 
Triplicate 100 ~l aliquots of the DNase digested and 
undigested mixtures were taken for assay of free ADA 
-
based on the Ginsberg and Keiser (67) method as 
follows: 
To each of the triplicated 100 ~l aliquots was added 
100 pl of a 10 pg/ml lambda DNA solution prepared as 
described below, and vortex mixed. The samples were 
incubated for 20 minutes at 37°C and then placed on 
ice and diluted rapidly by the addition to each,of 
the 4 ml ice cold SSC solution (0.15 M NaCl, 0.015 M 
sodium citrate). The diluted assay mixture was then 
passed through 0.45 ).lill cellulose nitrate membrane 
filte.rspresoaked in SSC and then washed with 3 x 4 ml 
volumes of SSC solution. The washed filters were 
then placed in glass scintillation vials and allowed 
to dry. After the addition of 6 ml of a commercially 
prepared scintillation mixture (Packard) the radio-





The mean of the counts of the triplicated undigested 
samples was subtracted from the mean of the digested 
samples. Using the following formula the DNA-IC 
levels, in pg DNA bound/ml serum, hereafter referred 
to as units/ml, were calculated as follows: 
DNA-IC =(x1 counts/min - x2 counts/min)x22(=Dilution facto r) 
Specific Activity.(= counts/min/µg 3H-DNA) 
Where -xl -- f th d' t d 1 mean o e 1ges e samp es 
-2 x = mean of the undigested samples 
The result was taken to be significant at a probability 
of < 0. 02 when comparing the triplicated measurements 
fer the DNase digested and undigested samples. 
Lambda DNA Preparation 
Lambda DNA was prepared by a modification of the method 
outlined by Thomas and Davis (301). 
Labelled lambd~ bacteriophage dsDNA was obtained by 
·productive infection of a K 12 strain of E coli 
obtained from Prof W du T Naude. The organisms 
were inoculated into oxoid nutrient broth No 2 (ONB) 
and cultured overnight. 2.5 ml of the culture were 
added to 250 ml ONB No 2 medium and incubated at 37°c 
with vigorous aeration for 3 hours to yield a count 
of approximately 108 cells/ml. One drop of silicone 
100 
antifoam was added to prevent overflow. At this 
stage 2.5 ml stock lambda phage were added and the 
incubation with aeration continued for a further 30 
minutes. From predetermined growth curve data 
(by periodic sampling for phage titration and optical 
density of . . 125 measured at 500 nm}, either 
2-14c-thymidine or methyl 3H-thymidine was then added 
at a final concentration of 0.2 µCi/ml, and 1 pCi/ml, 
respectively. Incubation was continued for a further 
30 minutes by which time phage-induced lysis was 
indicated by visible clearing of the incubation mixture. 
After lysis, CHC1 3 , was added to 0.5% (v/v) and the 
culture placed on ice. Bacterial debris was removed 
by centrifugation at 6000 rpm for 30 minutes using 
the 3015-BR4 rotor in a Sorvall S?perspeed RC-2B 
centrifuge. The phage was then pelleted by centri-
fugation at 35000 rpm for 1 hour in the Ti 60 rotor 
of a Beckman Model L 2-65B ultracentrifuge at 4°c. 
-3 The phage pellet was resuspended in 1 ml of 10 M MgC1 2 , 
l0-2M Tris-HCl, pH 8. The sample was then layered 
on a CsCl step gradient consisting of 0.5 ml 4.8 M CsCl 
(e = 1.6 gm/cm3), 0.5 ml 4.0 M CsCl (e = 1.5), 1 ml 
3.2 M CsCl (~ = 1.4) and 1 ml 2.4 M CsCl (€ = 1.3) 
-3 -4 -2 prepared in 10 M MgS04 , 10 M EDTA and 10 M Tris-HCl, 
pH 8. Centrifugation was carried out at 30000 rpm 
in the SW 50.l rotor of a Beckman Model L 2-65B 
ultracentrifuge. The phage layer, identified as a 
fine band above the 4.0 M CsCl layer, was removed with a 
1 ml syringe and a 25 gauge needle or with an LKB 
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4 
perpex pump at slow speed, mixe d with an equal v olume 
of saturated CsCl sol~tion a nd overlayered with 1 ml 
each of 4.8, 4.0 and 3.2 M CsCl. After a further 
0 centrifugation as above at 15-20 Ca single, clear, 
sharp phage band was ,visible towards the top of the 
tube. This reverse step gradi ent was performed to 
eliminate bacterial DNA cont amination. The band 
was removed and the DNA extr acted by placing the 
. 
phage in a dialysis bag (pre-washed several times in 
a l0- 2M Na
3 
EDTA, l0-2M NaCl, NaHC03 and absolute 
ethanol solution) and dialysed for 16 hours against 
500 ml 50% v/v formamide, 0.1 M Tris-HCl, pH 8.5 and 
-2 10 M Na 3 EDTA at room temperature. The dialysis 
bag was then transferred to 0.1 M Tris-HCl, pH 7.5, 
-J 0 
10 -M Na 3 EDTA for a further 24 hours at 4 C. 
The specific activity was determined using a con-
version factor of 58 pg/ml/unit absorbance at 260 nm, 
and the DNA diluted in Tris-HCl buffer so as to con-
tain approximately 10 pg DNA/ml. The DNA was sheared 
to a constant size by vigorous vortex mixing and by 
filtering through a 0.45 pm millipore filter before 
use. 
Restriction Endonuclease Digestion 
0.5 pg aliquots (7 ).11) of 3H lambda DNA were added 
to 43 ~l of the appropriate restriction endonuclease 
digestion buffers (see Miles .Biochemical Catalogue 
1979-80) and 3 units of either Bgl II, Hind III or 
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Eco Rl restriction endonuclease. Incubation was 
for 1.5 hours at 37°c and 16 hours at 4°c. 
Unlabelled wild type lambda DNA was digested 
~ 
in the same way. Analysis was on 1.2% 
agarose gels at lOOV for 2~ hours. The restric-
tion endonuclease studies are necessary to 
confirm that the DNA prepared is lambda in 
nature. This point is illustrated in Fig. 7 
which shows that the bands produced by restric-
tion endonuclease digestion of one of our 
putative lambda DNA preparations harvested 
as described, differs markedly from that of 
the control lambda DNA. 
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1 2 3 4 5 6 
.~ 
FIG. 7 Hind III and Bgl II restriction endonuclease 
digestion patterns of a putative lambda DNA prepara-
tion, compared with a wild type lambda DNA control, 
are shown. The band in gel 1 is that of the control 
lambda DNA, and on gels 2 and 3 the typical Hind III 
and Bgl II restriction endonuclease patterns respec-
tively. The band on gel 4, produced by the putative 
lambda DNA preparation is indistinguishable from that 
of the control but the Hind III and Bgl II restriction 
endonuclease patterns in gels 5 and 6 show that the 
nucleic acid harvested was not lambda DNA. 
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RESULTS 
Circulating complexes are quantitated 1n terms of the 
quantity of antibody released by DNase digestion of the 
antigen component of the complex, and the units therefore 
express the DNA binding capacity of the ADA in a situation 
of antigenic excess, namely, ..ug DNA bound/ml of serum. 
Since the units for IC levels are the same as those for 
expressing the free ADA in the serum, it was decided to 
express the quantity of DNA-IC as units/ml in order to 
avoid confusion. 
The accuracy of bisecting the filters into two equal 
halves was determined by comparing the weights of each 
pair of 25 cut filters. This gave a standard deviation 
of 3.1%. 
The percentage free ADA removed from the filters by washing 
with Tris-HCl buffer was evaluated by comparing the counts/min 
in the saline blank with those in the undigested sample. 
Typical results in 2 patients with high free ADA levels, 
and the% free ADA washed through the filters are shown in 
Table IV. It was found that the degree of sensitivity 
of the assay was not affected by the levels of free ADA, 
even in excess of 100 )lg DNA bound/ml serum since the 
washing of the filter was effective in removing virtually 
all the free ADA. 
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TABLE IV: The percentage removal of free ADA from the 
filters by washing with Tris-HCl buffer in 2 representative 
patients with SLE 
.:"' 
FREE ADA 
SALINE UNDIGESTED DIFFERENCE % ADA BLANK SA1\1PLE {pg DNA bound/ml) (x CPM) {X CPM) (CPM) REMOVED 
76 217 301 84 99.9 
114 266 266 0 100.0 
Negative values, significant at a probability of <:::"0.02, 
were not found more frequently than expected. 
For low levels at the limit of sensitivity for the assay the 
significance was determined by the student t test on the 
triplicated undigested and digested data values. Circulating 
DNA-IC levels were taken to be si9nificant at a P value of 
less than 0.02 for levels of 0.03 units/ml or greater. 
The relationship between DNA-IC ahd ADA levels during· active 
SLE was investigated in a series of 40 patients, 37 of whom 
fulfilled the preliminary ARA classification criteria and the 
remaining 3 with unequivocal SLE. 
Five distinct categories of patients emerged: 
I Elevated free ADA levels with no complexes detectable. 
II Elevated free ADA levels and. low but significant levels 
of complexes. 
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III Elevated free ADA with relatively hig~ levels of 
complexes. 
IV Normal or only slightly elevated ADA and high 
relative levels of complexes. 
V Normal free ADA and undetectable complexes . 
. 
A representative patient from each of the categories is 
shown in Table V. 
TABLE V: Serological data of 5 representative patients 
with SLE from each of the categories based on free ADA 
and DNA-IC levels during active disease. 
CATEGORY -· · PATIENT . FREE ADA DNA-IC ().lg Dl-:A bound/ml) (units/ml) 
I JS 85 o.o 
II TN 129 0.41 
III MA 80 2.93 
IV NP 6 3.17 
V PR 0 o.o 
In a study of individual patients during active disease, it 
was found that the majority remained "true" to category 
irrespective of the system involved with each attack or 
whether they were tested early or late in the acute episode. 
An analysis of these parameters and of CH50 , singly or in 
combination, in relation to disease· activity is presented 
in Section IV. 
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DNA-IC levels were assayed in 20 normal subjects and in 20 
patients with active rhewnatoid synovitis. 
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The levels 
FIG. 8 DNA-IC levels in 20 normal subjects and in 20 
patients with active RA compared with levels found during 
76 acute episodes in 40 patients with SLE. 
Closed circles= 1 assay 
Open circles = 5 assays 
In normal subjects complexes were .undetectable in 19 (95%), 
while in the remaining subject (5%) a level of 0.03 units/ml, 
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significant at the 0.02 level, was recorded. In the RA 
group complexes were undetectable in 18 (90%) patients, 
with levels of 0.10 and 0.13 units/ml in 2 (10%), signifi-
cant at the 0.02 level. By contrast there was a good 
correlation between DNA-IC levels and active SLE, both 
quantitatively and qualitatively, elevated levels being 
present in 47 of 76 (62%) active episodes in the 40 patients 
studied, reaching levels as high as 16 units/ml. 
The possibility that complexes small enough to pass through 
the 45 ~m millipore filter and thus escaping detection 
was investigated by refiltering through 0.22 ..urn filters, the 
effluent from the 45 pm pore size filters used in the standard 
assay. In none of the samples tested was complex material 
detected on the 0.22 ~m filters. 
The further possibility considered was that a proportion of 
the material detected by this assay is due to nonspecific 
aggregates rather than true complexes. DNA-IC's were 
therefore measured in freshly collected lupus sera and 
compared to levels in aliquots of serum either heat 
inactivated at 56°c for one hour, or repeatedly frozen 
and thawed or heat inactivated plus freezing and thawing, 
conditions known to promote the formation of aggregates. 
In none of the samples tested in this way was there any 
difference between complex levels in the control sera when 
compared to either heat inactivation or repeated freezing 
and thawing. In only one of the samples which was both 
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heat inactivated and repeatedly frozen and thawed was there 
a significant increase (P <0.02) of 0.18 units/ml over the 
control. 
To ensure that there was quantitative release by DNase 
digestion of antigen from the complexes bound to filters, 
artificial complexes were prepared by the addition of a small 
quantity of 14c-DNA to the serum of patients with known 
high levels of free ADA and no circulating complexes. The 
proportion of 14c-DNA released by DNase treatment from the 
artificial complexes bound to the filters and of the control 
samples without DNase showed that binding of more than 95% 
to the filter is obtained in the former, and release is 
virtually quantitative. The minor quantity of counts 
released into the supernatant from the half filter not 
exposed to DNase presumably reflects dissociation of ADA 
from the complex since virtually all the free ADA is re-
moved from the filters by the washes as referred to earlier. 
The kinetics of DNA binding to ADA was investigated by 
adding an excess of labelled DNA to serum containing a high 
0 level of free antibody and incubating at 37 C. DNA binding 
was measured before incubation and in duplicate samples 
removed at 2~, 5, 10, 20, 30, 60, 120 and 240 minute 
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FIG. 9 The kinetics of DNA binding. 
DNA binding to ADA is rapid, 94% occurring by 60 mins. 
The.reafter the curve flat tens out and the reaction is 
virtually complete by 240 mins. 
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DNA-IC levels were measured in 16 patients with SLE and 
compared with the% binding by the c1q assay (302), a 
technique which has only recently become available to us 
as a routine assay. The preliminary results are shown in 
Table VI. Levels in excess of 3% binding by the 
c1q assay, and more than 0.03 units/ml for the DNA-IC 
assay are taken as significant. 
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TABLE VI: DNA-IC and c1q binding assays in 16 patients 
with active and inactive SLE. 
PATIENT Clq binding DNA-IC ACTIVITY (%) (units/ml) 
1 6.8 0.41 + 
2 1.4 0.00 
3 12.9 o. 92 + 
4 13.1 2.35 + 
5 2.0 . 0.14 + 
6 1.6 o.oo + 
7 5.3 0.00 + 
8 1.4 o. 30 
9 1.5 0.03 
10 1.7 0.13 + 
11 7. -g o.oo 
12 1.0 o. 40 + 
13 2.1 0.04 + 
14 45.0 -1.05 + 
15 6 .o o. 28 + 
16 8.5 o.oo 
The results show that in the 11 patients with active SLE, 
levels by both techniques were abnormal in 5, elevated 
DNA-IC levels with normal c1q binding were present in one, 
and in one patient only the c1q showed significant binding. 
In one patient with active disease both DNA-IC and c1q 
binding were within normal limits. In inactive SLE, levels 
were normal by both assays in one patient while in the 
remaining 4 patients, 2 had normal DNA-IC levels with 
significant c1q binding, and 2 had elevated DNA-IC levels 
with normal c1q binding. While of interest, the numbers 
112 
are too small for an analysis of the data. 
DISCUSSION 
The need for the development of new assays for the measure-
ment of IC's in SLE was emphasised in two recent editorials 
(303,304) as there is considerable evidence that IC's 
deposited in tissues can induce pathological lesions such 
as vasculitis and glomerulonephritis. As far as SLE 
is concerned our understanding of the pathogenetic mechanisms 
involved has been greatly increased since IC's have been 
studied more carefully. While of undoubted value, most 
of the assays currently available lack specificity and the 
antigens involved are unknown (245,253,254). While Jt is 
likely that IC systems other than DNA may be of importance 
in th~ pathogenesis of the disease, it has been established 
that antibodies to dsDNA in serum are highly specific for 
SLE (68) and there is furthermore strong evidence that 
DNA-IC's play an important role in the pathogenesis of the 
disease (188,189). 
Harbeck et al (117) described a method for determining 
specific concentrations of DNA-IC's in sera and showed that 
they are present during active disease, and also found that 
their presence correlates with nephritis (117,119,120), one 
of the major causes of mortality in the disease. Adequate 
accuracy by their method was only obtained by analysis of 
the samples in q u i ntuplicate. It also lacks sensitivity. 
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The method developed in our laboratory for the detection of 
specific DNA-IC's is an extension of the principle ~sed by 
Ginsberg and Keiser for the measurement of ADA by millipore 
-~ 
filtration (67). In their method sufficient labelled DNA 
(antigenic excess) is added to serum to form artificial 
complexes with all the free ADA present. These complexes 
are then trapped on a cellulose nitrate millipore filter 
while any unbound DNA passes through (305), and the ADA is 
expressed in terms of the DNA bound in the form of these 
artificially created complexes. In our method any naturally 
occurring complexes are trapped on the filter by prefiltering 
the serum diluted in Tris-HCl buffer to ensure that the 
filter is uniformly covered while virtually all the free 
ADA passes through, assisted by the 3 washes with Tris-HCl. 
All the ADA released from the natural complexes by DNase 
digestion is then ?Ound to the added radioactively labelled 
DNA to form artificial complexes and the DNA-IC levels are 
calculated in terms of DNA bound/ml serum. In order to 
avoid confusion with the units used for the standard free 
ADA assay, DNA-IC levels are expressed as units/ml. 
A crucial step in the assay is the ability of DNase to 
release the DNA bound to ADA in the form of complexes 
trapped on millipore filters. DNase was shown to effectively 
release more than 95% of the bound DNA. 
Mg++ facilitates the action of DNase while EDTA, which 
inhibits the action of DNase, is added at the end of the 
incubation period to stop the reaction. 
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While DNA prepared from rat hepatoma cells is used succe ss-
fully in the assay, we prefer to use lambda DNA since the 
counts in the undigested samples and in the saline blanks 
are lower than with rat hepatoma DNA. This is presumably 
due to the more uniform size and lower molecular weight 
(30 million) of lambda DNA. These factors would reduce 
the tendency of the DNA to form clumps which may be trapped 
on the filter. 
It was important to determine the accuracy with which the 
filters were bisected since the quantitation of complexes 
in the serum is a measure of the difference between the 
counts registered for the DNase digested and undigested 
half-filters. The results obtained were taken into 
account in the evaluation of the assay. 
Ideally a control serum containing a known quantity of 
DNA-IC should be included with each assay. Apart from 
the lack of available control samples in sufficient quanti-
ties (0.5 ml per assay) which precludes their inclusion 
as a routine procedure, it should be established whether 
DNA-IC's remain stable with prolonged storage. A solution 
to the problem of a control would be the preparation of 
standard quantities of artificial ·DNA-IC's. 
The object of refiltering the effluent from the 0.45 ,um filter 
through filters of smaller pore size was to establish whether 
small complexes escape detection. Our data suggests that 
this is not the case. However, it is not possible to 
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equate the molecular weight of complexes with their ability 
physically to pass through millipore filters. A more 
direct study of the complexes themselves is necessary to 
determine the characteristics of the DNA-IC's detected by 
this assay. 
An important issue and one which plagues many current assays 
is whether nonspecific aggregates rather than true complex 
material is being detected. Since nonspecific binding 
of DNA to, or entrapment by aggregates may occur, and since 
aggregates of sufficient size may be trapped on millipore 
filters, it is possible that some of the material detected 
by this assay is not true DNA-IC . in nature. Some of the 
factors known to promote the for-nation of aggregates were 
therefore investigated. Our studies have shown that 
neither heat inactivation nor freezing and thawing affected 
the DNA-IC levels. In only one instance did these factors 
in combination give rise to a small, but significant increase 
over the levels in the control sample. In order to avoid 
such increases as far as possible, heat inactivation is no 
longer performed. Because it is not always possible to 
perform the assay immediately, samples which have been 
frozen only once are used, and assayed within a few days of 
collection. It is likely that most of the counts on the 
filters of the undigested samples are due to DNA binding 
to nonspecific aggregates. By subtracting these counts 
from those in the digested samples and by adhering ·strictly 
to the measures already mentioned, we believe that the 
values obtained reflect almost exclusively true circulating 
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DNA-IC levels. 
Why patients with SLE should show such a wide variation in 
free ADA and DNA-IC levels during active disease is not 
clear, especially since no correlation was demonstrable 
between the pattern of the serological parameters and the 
nature of organ involvement or of the timing of sample 
collection during the acute episode. Factors pertaining 
to the size and properties of the free antibody and 
of the complex itself, and to the site of complex formation 
almost certainly play an important role in this respect. 
From the data presented, the DNA-IC assay appears to be 
specific for SLE especially for levels in excess of 0.13 
units/ml since in none of the 10% of the control and RA 
group where complexes were detectable were these levels 
exceeded. Because of this specificity the assay is of 
diagnostic value. On the other hand, the diagnosis of 
SLE cannot be excluded where complexes are not detectable 
since this occurred in 38% of patients with active, and 
in 68% with inactive disease (Section IV). In this 
respect the situation is analogous to the ADA assay. Data 
will also be presented showing that actual complex levels 
correlate with the severity of the acute attack. 
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SECTION IV: C L I N I C A L A P P L I C A T I O N 
0 F T H E D N A I M M U N E 
C O M P L E X A S S A Y I N S L E 
• 
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MATERIALS AND METHODS 
1 Patients 
Forty patients were studied prospectively. 
They were selected from ward admissions and from 
patients attending the lupus clinic at Groote Schuur 
Hospital which serves all the racial groups namely 
Negro-Caucasoid, Caucasian and Black living in the 
metropolitan area of Cape Town and the Western Cape. 
The selection of patients was based on the clinical 
picture so as to include as wide a spectrum of the 
disease as possible during both active and inactive 
phases. Serial studies were conducted on 8 patients 
and during plasma exchange on one patient. 
Of the 40 patients, 37 were women and 3 were men, 27 
were Negro-Caucasoid, 8 were Caucasian and 5 were 
Black. Their ages ranged from 15 years to 54 years 
(mean 30). Eight were studied during the initial 
presentation of SLE while in the remaining 32 patients 
the duration of the disease ranged from 1 to 26 years 
(mean 5.9). 
Thirty seven patients (92.5%) satisfied the preliminary 
criteria of the ARA for the classification of SLE 
(36-41). The three patients (7.5%) not fulfilling 
the criteria were considered to have unequivocal 
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evidence of SLE on the following grounds: One 
patient presented with acute polyarthritis, an 
erythematous butterfly rash, pericarditis, fever 
and severe depression with hypocornplementaemia, 
ANA positive to a titre of 1000 and significant 
elevation of ADA levels. The second patient had 
a long-standing history of non-deforming polyarthritis, 
neuropsychiatric manifestations and a butterfly rash 
-
with ANA positivity, hypocornplementaemia, significant 
ADA elevation and granular casts on a number of 
occasions during the course of the disease. The 
third patient presented with generalised cutaneous 
vasculitis, polyarthritis and alopecia with ANA 
positivity and ADA elevation. 
Flow sheets were designed to record: 
a) The presence or absence of clinical activity, 
and in the case of active disease the nature of 
the manifestations, 
b) the therapy administered, and 
c) the laboratory results. 
The patients were assessed by the author at each 
visit for evidence of clinical activity and graded 
accordingly. This was done before the results of 
the laboratory investigations were known. The 
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manifestations considered to be indicative of active 
SLE after other causes had been excluded are listed 
in Table VII. 
TABLE VII: Parameters used in the assessment of 











Tenosynoviti~ Synovial effusion 







Erythematous butterfly rash 
Exclusions: Raynaud's phenomenon, 
CDLE, Photosensitivity, Pigmentory 
changes, leg ulcers, ? digital 
gangrene 
Red cell or granular casts 
Active involvement on histology 
Significant or increasing proteinuria 
Azotaemia 
Increasing impairment of GFR 
Psychosis Coma 
Recent neuropsychiatric manifestations 











Flares were classified as minor, major or life-
threatening depending on the severity and nature of 
the involvement, and on the therapy ,required to control 
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the flare. A flare was judged to be minor if non-
steroidal anti-inflammatory agents were sufficient 
to control musculoskeletal symptoms or if skin lesions 
could be a&equately controlled with local corticosteroid 
applications. Major flares usually required admission 
to hospital and almost invariably corticosteroid 
and/or immunosuppressive therapy to achieve control 
of the flare. Life-threatening episodes consisted 
-of that small group of p·atients presenting with 
severe fulminating cerebral, renal or multisystem 
disease which are often unresponsive to therapy. 
Laboratory Tests 
At each visit urine was examined chemically and 
microscopically, and blood was drawn for the following 
investigations: 
a) Serum complement 
CH50 was assayed on freshly collected serum based 
on the method of Kent et al (306). The lower 
limit of the normal range was 160 units/ml. 
b) Anti-DNA antibody 
ADA was quantitated on serum stored at -20°c by 
a modification of the millipore filtration 
technique of Ginsberg and Keiser (67) using rat 
hepatoma cell (pp 67-69) or .,\DNA prepared from 
the Kl2 strain of E coli labelled with methyl 
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3H-thymidine or 14c-thymidine as described on 
pp 100-103. The normal range for our laboratory 
is between O and 5 µg DNA bound/ml serum. Levels 
of between 5 and lS _are regarded as suggestive, 
while levels above 15 ,ug DNA/ml are virtually 
diagnostic of SLE. 
c) DNA immune complex 
. 
Specific DNA-IC's were assayed by the millipore 
filtration and DNase digestion technique as 
outlined on pp 98-104. 
d) Where indicated, other investigations including 
full blood count, serum chemistry, tests of renal 
function, renal or other biopsies, radiological 
and neurological tests were performed. 
The following correlations between the clinical 
evaluation and the serologic parameters were determined: 
i} The clinical status and the coincident CH50 , ADA 
and DNA-IC levels, where for statistical analysis 
the clinical status was designated active or 
inactive, and each of the parameters as normal 
or abnormal. 
ii) The relationship between different grades of 
disease activity and actual coincident DNA-IC 
levels, and 
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iii) The relationship between elevated levels of 
DNA-IC in patients with clinically inactive 
disease and the subsequent development of 
flares in these patients. In this instance 
actual DNA-IC levels and the grade of activity 
which ensued. were evaluated. 
3 Statistical Evaluation 
The relative risk of the disease being active when 
any one of the three parameters, CH50 , ADA and DNA-IC 
was abnormal, was determined from Haldane's modified 
formula described elsewhere (307-309) . 
. This formula allows for the inclusion of both normal 
and abnormal levels of each parameter present in 
both active and inactive disease and also corrects 
for those instances where the numbers are relatively 
small. 
The entries of the appropriate 2x2 table were a, b, 









number of abnormal levels in active disease 
nwnber of normal levels in active disease 
nwnber of abnormal levels in inactive disease 
nwnber of normal levels in inactive disease 
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Thus, the relative risk, X = (2a+l) (2d+l) 
(2b+l) (2c+l) 
y is the natural logarithm of x (In x), with a 
variance given by 
V = 1 + 1 + 1 + 1 
a+l b+l c+l d+l 
and weight, w = 1/V. 
The significance in each case wa5 estimated by calcu-
lating;(2 = wy2 and Fisher's exact probability (P) 
values. 
By selecting a, b, c and d for each parameter and using 
the same formula, the relative risk of the disease being 
active when two or all three parameters in combination 
were either normal or abnormal, was also determined. 
Even though the relative risk may appear to be higher 
in certain combinations, Fisher's exact P value, which 
takes into account differences in sampling size, is 
used to assess the true sign~ficance. 
In order to establish whether there was a statistically 
significant difference in DNA-IC levels in the different 
grades of disease activity, the following hypotheses 
were tested: 
a) Null hypotheses (H0 ) ie. that the means of DNA-IC 
levels in the different grades were equal (H01 : 
..u1 = P 2 , H02 : ).12 = )13 and H03 : ).13 = p 4 for inactive/ 
minor, minor/major and major/life-threatening 
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disease respectively) where p = actual population 
mean. 
b) Alternative hypotheses (H1 ) ie. that the means 
were progressively higher for each grade of 
activity (H11 : pl< ).12 , H12 : ;12 <)13 and H13 : 
Jl3<).14). 
The test statistic, T, for the difference of means 
was chosen under the assumption of normality and 
equal but unknown population variances. 
T = 
sj ~ + ~ 
where x. = l means, i = 1,2 
s = the pooled standard deviations 
m = number in sample one 





and S2 = 
m + n - 2 
T hast distribution with m+n-2 degrees of freedom 
( t/ 2) • 
0\. ;m+n- · 
The significant levels,~, was set at 0.05. 
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RESULTS 
Of the 40 patients, 15 remained clinically inactive during 
the 30 month period of study while in the remaining 25 
patients 44 acute flares of the disease were recorded. In 
the latter group 13 were on corticosteroids and/or immuno-
suppressive therapy at the time of the flare. The dosage 
was increased in 9 patients in order to control symptoms, 
while therapy was instituted in 9 who were not on therapy 
at the time of the flare. 
The clinical manifestations of the 25 patients who developed 
active disease and their relationship to the presence or 
absence of circulating DNA-IC are shown in Table 
Arthritis and skin involvement accounted for the majority 
of -active episodes both when they were involved alone 
(12 and 11 episodes respectively) or when involved as part 
of a more general flare with other organs (21 and 20 episodes 
respectively). 
Histological evidence of renal disease was present in 12 
patients. Of these 50% were focal or mesangial, 8% were 
membranous and 28% were mernbranoproliferative. In all 
these patients the urinary sediment was abnormal on numerous 
occasions, the nephrotic syndrome was present in three, and 
of the two patients with uraemia and low GFR one has died. 
The presence on one or two occasions of a few granular casts 
without deterioration in renal function in four patients 
during the study was not considered an indication for renal 
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biopsy. These patients were not included. 
TABLE VIII: Organ involvement in 25 patients who had 44 acute 
episodes of SLE in relation to the presence or absence of 
DNA-IC 
ORGAN NO. OF ACTIVE DNA-IC NOT 
INVOLVEMENT EPISODES PRESENT* PRESENT* 
Musculoskeletal 12 16 7 
Skin 11 10 8 
Renal 5 2 5 
Musculoskeletal/ 3 3 2 Skin 
Skin/CNS 2 4 1 
Musculoskeletal/ 
2 2 2 CNS/Renal 
Skin/Renal 2 2 1 
CNS 1 1 
Musculoskeletal/ 
1 2 Skin/Renal 
Thrombocytopenia 1 1 
Pericarditis 1 1 
Musculoskeletal/ 
1 1 Renal 
Musculoskeletal/ 
1 2 1 CNS/Pleurisy 
Musculoskeletal/ 
Skin/Renal/Peri- 1 1 1 
carditis/Lung 
TOTAL 44 47 29 
* Number of assays 
A total of 136 IC assays were performed, 76 during active 
and 53 during quiescent phases of the disease (total:129). 
The remaining 7 were additional assay's performed over a 24 
hour period on two patients during active disease. The mean 
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of these levels for each patient was taken as representing 
one IC level in terms of the particular episode. ADA levels 
were measured in 188, and CH50 in 176 samples from the 
patients during the same period of study. The results obtained, 
the relative risk of disease activity for each parameter 
separately and in combination, the chisquare and the P values 
are shown in Table IX. 
Abnormalities of the three ~arameters either singly or in 
combination, were all significant as monitors for the pre-
sence of active disease. Of the parameters assessed 
singly, CH
50 
was better th~n either ADA or DNA-IC. When 
two parameters were assessed in combination the values 
obtained for ADA+ DNA-IC and for CH50 + DNA-IC were sig-
nificantly better than for any of the parameters singly 
or for ADA+ CH50 . l'he combination of all three parameters 
while superior to ADA+ ctt50 did not reach the significance 
Qf either CH50 + DNA-IC or ADA+ DNA-IC as tests of active 
disease. Furthermore it is noteworthy that CH
50 
as a 
single monitor is better than ADA+ CH50 . Thus, the 
most useful combination of monitors are firstly, 




















































































































































































































































































































































































































































































































































































DNA-IC levels in active and inactive disease are shown in 
Fig. 10. The highest levels for inactive disease and for 
minor flares were 1.77 ~and 1.63 units/ml respectively. 
Except for one level of 7.40 units/ml recorded in a patient 
with a major flare, levels above 3.50 units/ml were confined 




































FIG. 10 DNA-IC levels in active and inactive SLE are shown. 
Complexes were undetectable in 36/52 (69%) patients with 
inactive disease and in 16/26 (61%) with minor, 12/46 (26%) 
with major and in 1/5 (20%) with life-threatening disease. 
Full statistical analysis of levels in the various grades 
is shown in the following table. 
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In Table X, the data obtained from an analysis of DNA-IC 
levels in the different grades of disease activity shows that 
while the difference between DNl~-rc levels in inactive dis-
ease compared to minor activity is not significant, the mean 
levels in the three groups, inactive/minor, major and life-
threatening activity, are significantly different at the 0.02 
significance level. It should however be noted that in the 
life-threatening category there were only five samples. 
TABLE X: Statistical analysis of DNA-IC levels in patients 
with active and inactive SLE. 
Inactive Minor Major 
Life-
Statistic Threatening n=52 n=26 n=46 n=5 
- * X 0.16 0.19 0.74 6.47 
s ** 0.43 
X 
0.44 1.33 6.72 
*** I s 0.06 0.09y 0.20~ 3.10 
X ':,/ 
S2 0.19 1.21 5.33 
s 0.43 1.10 2.35 
T -0.29 -2.04 -5.18 
t 0.05,m+n-2 1.67 1.67 1.68 
T>-t T <'.-t T <-t 
Accept H 
0 
Accept H1 Accept H1 
().11 = J.12) (J.12 < J.13) (J.13 < )14) 
* = estimated sample mean 
** = standard deviation 
*** = standard error of the mean 
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Five of the patients (12%) died, one from uraemia and 
cerebral involvement, two from cerebral lupus, one ~rom 
suspected cerebral lupus (who died at home), and one from 
.~ 
myocardial infarction, polyserositis, pulmonary oedema and 
a midbrain haemorrhage. Of the deaths only one occurred 
during the study. In the remaining four patients none 
had previously had life-threatening disease, three had 
had major, and one had had minor episodes in the past. 
Of the two patients who survived life-threatening episodes 
one has remained in remission and the other has been lost 
to follow-up. In the other two groups two patients with 
major and one with minor disease have been lost to follow-
up. The clinical course of two of these patients, the 
one who died during the study and one of those who died 
from cerebral lupus subsequent to the study, are described 
later in this Section. 
Those patients in whom DNA-IC's were present without evidence 
of clinical activity were observed for the subsequent de-
velopment of active disease. The outcome of this group of 
11 patients in whom 17 elevated DNA-IC levels were recorded 
is shown in Table XI. Three patients did not develop any 
evidence of active disease over the 30 month period of obser-
vation, 6 (55%) had minor and 2 (18%) had major flares. The 
onset of the active episodes ranged from 1 to 9 months. As 
shown on the Table, where more than one IC level in any par-
ticular patient was measured during inactive disease, each 
has been related individually to the onset of the active 
episode. One patient who developed a minor flare died 11 
133 
months later from suspected cerebral lupus. The levels of 
DNA-IC recorded bore no relationship to the severity of the 
acute episodes which developed. 
TABLE XI: Outcome in 11 patients with SLE in whom DNA-IC 


























































* Died 11 months later from suspected cerebral lupus. 
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Evidence of previous renal involvement wa s sought in the 
same group of patients, namely those with increased DNA-IC 
levels with no evidence of clinical activity. Definite 
histological evidence of renal lupus was present in 6 of the 
patients, accounting for 11 of the 17 elevated DNA-IC levels 
in the group of patients with inactive disease. Two further 
patients in this group (who were not biopsied) had had 
granular casts on a few occasions while the remaining three 
had never shown any evidence of renal "involvement. 
The clinical course and management in 2 of the 3 patients 
with life-threatening disease are described on pp 141 and 
149. There was no uniformity in the pattern of the three 
laboratory parameters in any of these patients. In Patient 
9 ADA levels in excess of 1000 ).lg DNA bound/ml serum were 
present with high IC levels and unrecordable CH50 . In 
patient 4 who subsequently died there was never more than 
a modest increase in IC and ADA levels. In the third 
patient the presentation was that of polyarthritis, alopecia, 
butterfly rash, pericardial effusion, and vasculitis. 
Laboratory investigation revealed positive LE cells on 
numerous occasions, a biological false positive test for 
syphilis, unrecordable CH50 , ANA 2500, ADA elevation, 
leucopenia, Coorr~s positive haemolytic anaemia and granular 
casts. During the time that high circulating complexes 
were present in this patient, 6 assays were performed over 
24 hours. The levels were the highest yet recorded by 





In 1971 this patient, an Asian male (IM) aged 14 years 
was diagnosed as viral encephalitis. Four months later 
he was readmitted with the nephrotic syndrome, micro-
scopic haematuria and granular casts in his urine. LE 
cells and ANA were positive and complement levels were 
unrecordable. 
azothiaprine. 
He was treated with prednisone and 
In 1977 he developed a butterfly rash, 
alopecia, oral ulceration and a Coombs positive haemolytic 
anaemia. LE cells and ANA were again positive and the 
ADA was 86 .).lg DNA bound/ml serum. Proteinuria of 
8g/24 hours ~nd numerous granular casts were present. 
The only available information of the renal histology 
was of focal hypercellularity with capsular adhesions. 
His subsequent course has been one of frequent polyarthral-
gia, cutaneous vasculitis, oral ulceration, memory 
impairment, headaches, unexplained chest pain and malaise. 
In July 1979 there was an exacerbation of the nephrotic 
syndrome. A renal biopsy revealed diffuse membranous 
changes with hypercellularity, segmental hyalinisation, 
pericapsular adhesions, fibrosis and areas of calcification. 
Treatment consisted of high-dose corticosteroids and 
cyclophosphamide. 
Serial studies of CH50 , ADA and IC levels over9 months 
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A good correlation between CH50 and DNA-IC levels in active 
and inactive disease is demonstrated. Of interest is the 
appearance of circulating complexes one month before the 
major flare, and the fact that ADA levels throughout 
the course remained within normal limits apart from two 
minor elevations. 
PATIENT 2 
At the age of 30 years this White female patient (CP) 
developed seronegative polyarthritis. SLE was established 
some years later on the grounds of alopecia, LE cells, a 

























and ADA elevation. Her course has been one of inter-
mittent episodes of polyarthritis, urticaria, blotchy 
erythematous skin lesions, malaise and depression . 
The serological data over a 6 month period of active 
disease is illustrated in Fig.12. 
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In this patient there was persistent elevation of ADA and 
DNA-IC levels in addition to hypocomplementaemia throughout 











This 53 year old Coloured female (MA) presented in May 
1977 with polyarthritis, vasculitic skin lesions, thrombo-
cytopenia, and Coombs positive haemolytic anaemia. LE 
cells were present, ANA was positive to a titre of 2500 
and an ADA level of 80 .J.lg DNA bound/ml serum was present 
on admission. Urinalysis revealed normal chemistry but 
on microscopy numerous granular casts were noted. A 
renal biopsy showed the features of diffuse membrano-
proliferative nephritis and subendothelial and subepithelial 
deposits were demonstrated on electronmicroscopy. Therapy 
with high-dose corticosteroid and cyclophosphamide was 
instituted. An initial creatinine clearance was 87 ml/min. 
This fell to 38 and gradually reverted to normal over the 
next two months. The patient became asymptomatic after 
three months of therapy and apart from intermittent episodes 
of microscopic haematuria and granular casts there was no 
evidence of active disease. At no stage had there been 
any evidence of cerebral involvement but in January 
1980 she developed acute cerebral lupus and died 3 days 
after admission despite intensive therapy. 
ADA, CH50 , and IC levels at presentation and over the 
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Undetectable CH
50 
and high ADA and DNA-IC levels accompanied 
the initial presentation in this patient. Thereafter the 
levels of the three parameters remained essentially normal 
despite subsequent episodes of active disease. 
PATIENT 4 
A diagnosis of SLE was made on this White female patient 
(PR) aged 33 years at the time on the basis of nephritis, 
polyarthritis, alopecia, butterfly skin rash, severe 
Raynaud's phenomenon, neurological involvement, positive 
LE cells and high titre ANA. Her course over the years 
was stormy, punctuated by episodes of digital gangrene, 
141 
lethargy and persistent hypoalbuminaemia which, despite 
intensive investigation for evidence of malabsorptipn, 
protein-losing enteropathy or as a ~esult of renal or 
hepatic involvement remained unexplained. She developed 
hypertension and terminally her renal function deteriorated. 
She was admitted to hospital with a myocardial infarct in 
A1j_gust 1977 and died 14 days later. Autopsy revealed coronary 
atherosclerosis, subendocardial anteroseptal myocardial 
infarction, polyserositis, Libman-Sacks endocarditis, 
pneumonitis, a solitary hepatic angioma~ multiple renal and 
hepatic infarcts, pulmonary oedema and a midbrain haemorrhage. 
Unfortunately due to autolysis the kidneys and bowel were 
unsuitable for histological examination. 
Fig 14 illustrates CH
50
, ADA and IC levels over an 18 month 
period. The last series of figures reflect the situation 
3 days before her death. 
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Persistent hypocomplementaemia characterised the clinical 
course both during active and inactive disease. ADA and 
DNA-IC levels remained normal until the terminal episode. 
PATIENT 5 
The patient, a White male (TN) developed seronegative 
polyarthritis in 1970 at the age of 20 years. Two years 
later SLE was diagnosed on the basis of LE cells, 
leucopenia, positive ANA, hypocomplementaemia, proteinuria 
and granular casts. A renal biopsy was not performed 
at the time due to a persistently low prothrombin index 
and a prolonged KCT which did not respond to Vitamin K. 
He was treated with indomethacin and chloroquin initially 
but due to inadequate control was giv~n small doses of 
prednisone. A renal biopsy performed 4 years later showed 
mild mesangial proliferation, basement membrane thickening 
with complete fibrosis of some glomeruli. The major 
emphasis of his disease over the years has been on the 
musculoskeletal system. He has had recurrent episodes of 
tenosynovitis and has required surgery for spontaneous 
rupture of the right tendo Achilles, both patellar 
ligaments and the right fifth extensor tendon of the 
right hand. He has also developed marked Boutonniere 
deformities of his hands. 
His laboratory parameters during two musculoskeletal 
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In general a good correlation is present between the 
three parameters and acute exacerbations. During inactive 
disease complexes were undetectable but hypocomplementaemia 
and ADA elevation persisted. 
PATIENT 6 
This White female patient (JS) presented in 1974 at the 
age of 19 years with polyarthritis, a butterfly rash, 
photosensitivity, alopecia and pyrexia. LE cells were 
positive on numerous occasions, ANA was positive to a titre 
of 1000, and an ADA level of 70.).lg DNA bound/ml serum, 
hypocomplementaemi a and leucopenia were recorded. She 
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responded well to corticosteroid therapy but over the 
next three years had persistent polyarthritis, alopecia 
and active skin lesions which were not adequately controlled 
despite continued treatment with prednisone and non-steroidal 
anti-inflammatory agents. In August 1978 there was a 
flare of arthritis and she developed pericarditis. This 
episode was controlled with an increase of steroid dosage. 
Her subsequent course has been uneventful apart from an 
attack of herpes zoster and the development of granular 
casts in the urine. Renal biopsy revealed patchy increase 
in the mesangial matrix and focal hypercellularity. The 
basement membrane was normal. 
The serological findings during a phase of arthritis and 
cutaneous vasculitis, and also during the episode of 
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ADA levels followed the clinical course most closely. 
During the active episodes two of the three parameters 
(i.e. elevated ADA with either hypocomplementaemia or 
detectable complexes) were abnormal. 
PATIENT 7 
SLE was diagnosed in this White female patient (NP) in 1970 
. 
at the age of 28 years. The presenting features were a 
butterfly rash of the face, maculopapular eruption of the 
palms, Raynaud's phenomenon, polyarthritis, photosensitivity, 
a biological false positive test for syphilis, LE cells, 
thrombocytopenia and a positive Coombs test (without anaemia). 
In 1976 she developed hypertension, heavy proteinuria and 
granular casts in the urine. Renal hi~tology was that of 
membranoproliferative glomerulonephritis. She was treated 
with high-dose corticosteroids and cyclophosphamide. Apart 
from occasional episodes of cutaneous vasculitis and alo-
pecia (the latter possibly due to cyclophosphamide) she 
remained well clinically. A repeat renal biopsy in February 
1978 showed active focal proliferative changes. 
Fig 17 illustrates CH50 , ADA and IC levels measured 
during both active and inactive phases of this patient's 
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But for the appearance of complexes during the later 
stages of clinically inactive disease, a good correlation 
of the three parameters with the . clinical status is 
demonstrated. 
PATIENT 8 
This Coloured female patient (LJ) presented in 1972 at 
the age of 30 years with alopecia, Coombs positive 
haemolytic anaemia, positive LE cells on numerous occasions, 
positive ANA, ADA of 77..JJ.g DNA bound/ml serum and the 
nephrotic syndrome with heavy proteinuria and granular casts. 
In 1975 she developed pleurisy . Renal biopsy revealed focal 
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proliferative glomerulonephritis. She could not be 
adequately controlled on relatively high doses of prednisone 
and despite the addition of cyclophospharnide to the regime, 
"' 
control of the disease was not achieved. Polyarthralgia 
with significant morning stiffness has since developed and 
she still has persistent malaise, fatigue and the nephrotic 
syndrome. 
IC's were monitored with the usual indices of disease acti-
vity over a 7 month period
1
shown in Fig. 18. 
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In this patient who has never been in remission clinically, 
high levels of .ADA and significant levels of complexes 
were a persistent feature. By contrast hypocomplementaemia 
was only present intermittently. 
PATIENT 9 
At the age of 35 years this Asian lady (AM) developed 
severe polyarthritis, Raynaud's phenomenon, malaise, 
pleuritic chest pain, fever, headache, skin vasculitis 
and positive LE cells. Blood urea was normal with a 
creatinine clearance of 22 ml/min, and an ADA level of 
1063..,ug DNA bound/ml serum, hypocomplementaemia, ANA 
2500 and leucopenia were recorded. Renal biopsy revealed 
focal mesangial hypercellularity and wire-looping. IgA 2+ 
was demonstrated on immunofluorescence. She was treated 
with high-dose corticosteroids. Despite this she developed 
psychotic manifestations and convulsions. Cyclophosphamide 
was commenced and because of the severity of the presentation 
five plasma exchanges were performed over a 7 day period. 
There was a dramatic improvement in the clinical state 
apart from the psychosis. The latter resolved over several 
weeks and she was discharged on pred~isone and cyclophos-
phamide. Her subsequent course has been uneventful and 
she has remained in virtual remission over a 2 year period 
of follow-up. 
CH50 , ADA and IC levels before and after plasma exchange 
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The dramatic return of the three parameters to normal 





While the usefulness of the ARA criteria for the classifi-
cation of SLE is not disputed, a significant number of 
patients who are excluded from clinical or laboratory studies 
because of failure to fulfil the criteria undoubtedly do 
have SLE. 
In common with the experience of others (26-28) we have a 
number of patients with unequivocal SLE with a deforming 
arthropathy indistinguishable from RA. Still at a clinical 
level a number of patients attending our clinic who are 
not overtly psychotic, and who do not have any organic 
neurological disturbance or a history of epilepsy, at one 
time or another exhibit "odd" behavioural tendencies which 
are difficult to categorise and which we believe to be 
part of the lupus syndrome. With the introduction of the 
antineuronal antibody, LCA and 15 o2 scanning techniques, 
we hope to investigate further this aspect of minor neuro-
psychiatric manifestations in SLE. 
While the LE cell test, one of the AR.~ criteria, is still 
performed as a routine diagnostic test in SLE we find the 
ANA, while also nonspecific, and the ADA, which is more 
specific, of considerably more value in the diagnosis of 
SLE. The ADA is particularly useful as a diagnostic aid, 
since we found significant elevation of 15 ~g DNA bound/ml 
serum using our laboratory standards in 49% of 186 patients 
with SLE (which includes both active and inactive disease) 
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and in only 2% of 176 normal subjects. No levels in excess 
of 15 ~g DNA bound/ml serum were recorded in 21 patients 
with RA. 
The three patients included in the present series who do not 
fulfil the criteria ' for SLE should therefore not strictly 
be classified as such, but for the reasons mentioned, there 
was little doubt of the diagnosis and they were included 
. 
because they illustrate important aspects pertinent to the 
study. A revision of the criteria, which should at the 
very least include ADA, is awaited. 
The clinical evaluation of patients for evidence of disease 
activity poses a number of problems. While the assessment 
is relatively straightforward in most cases, particularly 
when there is objective evidence of arthritis, pleurisy 
or pericarditis or when typical skin changes are present, 
it may be extremely difficult in the case of renal or 
cerebral involvement. A number of schemes have been 
devised including the use of scoring indices, grading 
according to the degree of activity, criteria for major 
or minor flares or schemes based on the need for increased 
steroid therapy in order to control symptoms (80,100,310, 
311 ) • The system used in this study is based on these 
but with a few modifications. The need to institute steroid 
therapy or to increase the dose in those patients already 
on treatment permits a reasonably clear differentiation 
between minor and major flares. In our experience most 



















or immunosuppressive therapy. The third category of 
putients, those presenting with life-threatening disease 
was included in order to study the role of the DNA-IC in 
this small but important group separately. 
No system is entirely satisfactory since the evaluation has 
to depend on a number of subjective parameters such as 
malaise, fatigue, polyarthralgia or the duration of morning 
-
stiffness. Even some of the more objective parameters 
may be difficult to evaluate. As far as cutaneous 
manifestations are concerned Raynaud's phenomenon is not 
generally regarded as an index of disease activity and 
although difficult to treat is usually associated with 
milder disease (312). Whether leg ulcers, urticaria or 
·digital gangrene are indicative of activity is also open 
to question. In order to avoid as far as possible false 
positive assessments of activity these cutaneous manifes-
tations were not included in the scheme. 
Furthermore the question may be asked: Do cellular casts 
in the urine indicate active renal lupus? Red cell casts 
and "significant" numbers of granular casts are suggestive 
(310) but should not be used in isolation. Certainly their 
absence does not exclude active renal involvement as casts 
may be shed intermittently. If it were practical the 
total nurr~er of casts excreted in 24 hours would be of more 
value. The degree of, or an increase in proteinuria is 
I 










The absence of significant proteinuria however does not 
exclude active renal disease. It must be emphasised that 
before ascribing any of these manifestations to SLE itself, 
other causes must be considered and carefully excluded. 
The main object of this study was to evaluate a new specific 
DNA-IC assay in patients with SLE in the following terms: 
firstly, to establish whether its inclusion as a parameter 
_of disease activity is justified; secondly, whether their 
presence in the circulation in the absence of clinical 
activity may be used to predict the onset of active disease; 
thirdly, whether their presence in the circulaticn reinforces 
the concept that complexes with DNA are important in the 
pathogenesis of the disease. 
Us~ng a DNA-specific IC assay Harbeck et al demonstrated a 
correlation between IC levels and active disease (117,119, 
120). In their series as a whole DNA-IC's were present in 
58% of cases during acute episodes. This is in agreement 
with our data where circulating complexes were detected in 
62% of acute flares. They also claimed that increased 
levels were only presenu during active cerebral and/or 
renal lupus. Their latter claim was based on a subdivision 
of their series of 50 patients into 4 groups according to 
the predominant organ involved. Unless the criteria for 
the exclusion of certain organs are clearly defined, a system 
such as this must be viewed with caution. This is particu-
larly relevant to renal involvement where, as has been 
pointed out, normal renal function and urinalysis alone 
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are not sufficient to exclude renal activity. It was not 
stated whether renal biopsies were performed in all their 
patients. 
Biopsies were not performed routinely in our series during 
acute episodes unless there was clinical or laboratory 
evidence of renal involvement. Therefore a clinical 
subdivision such as Harbeck's was not attempted. 
The interesting correlations between the three serological 
parameters require comment. In the first instance, why is 
CH50 a better monitor of SLE than either ADA or DNA-IC? 
The most likely explanation would seem to be that CH50 
consumption occurs during the formation of any IC which 
-is complement-fixing, whether the complex is DNA in nature 
or not. Therefore if it is true that both DNA and non-DNA 
IC systems share in the pathogenesis of SLE it is logical to 
assume that CH50 would be a good monitor of disease 
activity providing that the complexes formed are complement-
fixing. 
Why the DNA-IC should be a better monitor of disease activity 
than ADA is also not clear but at least two possibilities may 
considered to account for this discrepancy. 
1 ADA in itself is not capable of producing tissue damage 
so that its presence in the circulation does not neces-
sarily imply that IC's are being formed and deposited. 
Circulating complexes on the other hand, because of 
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their potential to initiate tissue injury if deposited, 
are more likely to be associated with tissue damage 
and therefore with evidence of disease activity. 
2 Even if IC formation is an inevitable consequence when 
circulating ADA is present, the IC formed, because of 
its size (for example, large in a situation of anti-
body excess) or for some other reason,may be rapidly 
cleared by the RES so that tissue deposition does not 
occur. Because of the rapid clearance of large 
complexes from the circulation they are more likely 
to escape detection. 
Whatever the reasons, it has been shown conclusively that 
· the DNA-IC is a valuable adaition to the existing serological 
monitors of disease activity in SLE. 
With regard to the predictive value of the IC, 8 (73%) of 
the eleven patients with raised DNA-IC levels in the presence 
of inactive disease subsequently developed evidence of 
activity. While the numbers are too small to draw any firm 
conclusions, patients with detectable complexes should be 
observed more closely. As shown, however, it is not possi-
ble to predict the nature or the severity of the attack from 
the levels of circulating complexes although none of the 
levels was markedly elevated. A longterm study on a larger 
group of patients is at present in progress but if this small 
study is representative it would not seerr. logical to treat 
patients on the basis of raised IC levels alone. 
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The possibility that subclinical renal activ ity might have 
been present in some of the patients with elevated DNA-IC 
levels in clinically ina ctive disease cannot be excluded. 
The important question of whether elevated DNA-IC levels 
are a better monitor than CH50 or ADA for active renal 
disease can only be resolved by performing renal biopsies 
in all patients with increased IC levels whether or not 
evidence of renal activity is present at the time. 
A close relationship has been shown between DNA-IC levels 
and the severity of clinical manifestations in SLE. The 
difference in levels between inactive/minor, major and life-
threatening, allowing for the fact that there were only 5 
samples in the last group, was striking. This data susgests 
that DNA-IC may not only be of qualitative significance 
in SLE, but that quantitatively it may be of considerable 
importance in the pathogenesis of the tissue lesion. 
Tan et al (207) suggested that acute exacerbations in SLE 
are preceded by a rise in ADA levels and that, with the onset 
of symptoms, ADA disappears from the circulation and coincides 
with the appearance of free circulating DNA, implying that · 
DNA-IC formation is responsible for the clinical manifesta-
tions. 
In our experience, firstly, DNA levels bear no relationship 
whatsoever to disease activity in SLE. Secondly, while 
ADA levels pre ceeding acute attacks have been recorded in 
some of our patients this is by no means the rule. As 
157 
outlined in Section III (pl06) we recognise five 
categories of patients with respect to ADA and DNA-IC 
levels during acute exacerbations. 
The serial studies of these parameters in the patients 
described, while demonstrating a good correlation between 
the three monitors and the presence of active disease 
(Patients 1, 2, 3, 4 and in Patient 5 during her initial 
presentation) and inactive disease (Patients 2 and 5), 
this was by no means the rule, not only in the group as a 
whole but also in individual patients during different 
acute episodes. 
Of interest in Patient 1 was the finding that, while there 
was a good correlation between hypocomplementaemia and 
raised IC levels during disease activity, the free ADA was 
generally within the normal range or showed only mild 
elevation. DNase digestio-n showed that virtually all the 
ADA was present in the form of complexes and thus escaped 
detection. Furthermore hypocomplementaemia and IC 
elevations in this patient antedated the appearance of 
clinical manifestations by 6 weeks. He was receiving 
30 mg of prednisoreat the time and since it is not our 
policy to treat on the basis of laboratory parameters 
alone, additional therapy was not instituted. However it 
subsequently became necessary to institute immunosuppressive 
therapy which was continued for 8 months before control was 
achieved of the major flare which ensued. 
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This raises the suestion of whether earlier recourse to 
more aggressive therapy might have aborted or at least 
have modified the exacerbation with easier control of the 
disease. While earlier therapy might have benefitted 
this patient, the arguments against this approach have 
already been discussed. 
The clinical course of Patient 4 prior to her death was 
one of chronic low-grade activity characterised by per-
sistent hypocomplementaemia in the face of normal ADA 
levels and absent IC's, and it was not until her terminal 
illness that these parameters became abnormal. But for 
mild elevation of ADA levels in Patient 6, a similar trend 
was noted during her first acute attack. A possible 
explanation for this phenomenon of normal ADA and absent 
ICLs in the face of active disease is that other non-DNA-
coataining IC's which are complement-consuming played a 
role in the pathogenesis of the disease. An alternative 
explanation is that local formation of DNA COQplexes occurs 
as suggested by Izui et al (241). 
But for the cerebral manifestations, there was a striking 
improvement in the clinical condition after plasma exchange 
of Patient 9 who presented with life-threatening disease 
and high circulating IC's. This is in agreement with the 
experience of Verrier Jones et al (313) who found that 
patients with detectable complexes showed greater improve-
rnent than those without. The clinical improvement in our 
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patient was commensurate with the disappearance of IC's 
from the circulation and one presumes that they were of 
importance pathogenetically. The possibility cannot of 
course be excluded that non-DNA-containing IC's were also 
removed by plasmaphoresis. 
Also of interest in this patient is the fact that despite 
a life-threatening presentation there has been no major 
. 
recurrence of the disease after over two years of observa-
tion. It is possible that her future course will be one 
of minor symptomatology or of complete remission. This 
phenomenon of "once-only" disease has been noted in 
several (at least 12) of our patients observed over periods 
of between 2 and 20 years. This phenomenon in SLE is 
being increasingly recognised even in patients who present 
with major or life-threatening wanifestations. Whether 
earlier or more aggressive therapy in these patients bears 
any relationship to the long-term outcome is at present 
unknown. 
In conclusion two important questions must be asked: Firstly, 
has this new specific DNA-IC assay made a contribution to 
our understanding of the pathogenesis of SLE as an IC 
disorder? Secondly, is its inclusion as an addition~l 
parameter in the investigation and management of SLE 
justified? 
In answer to the first question, numerous studies have 
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· demonstrated the presence of DNA-containing IC material 
in organs such as the kidney and skin of patients with 
SLE suggesting that they are of importance pathogenetically. 
Furthermore, clinical studies have shown a good correlation 
between active disease and circulating IC's using various 
antigen nonspecific techniques for their detection. 
By contrast there are very few reports investigating the 
relationship between specific DNA-IC levels and disease 
activity. One of the reasons for this lack is the paucity 
of techniques available for their detection. 
Recognising the need for an additional assay which is both 
practical and easy to perform the principle of millipore 
filtration and DNase digestion was utilise&. The successful 
application of the assay is evidenced by the data obtained 
in the study of active and inactive SLE and may be summarised 
as follows: 
1 A good correlation was shown between active disease 
and the presence of DNA-IC, both as a single monitor 
(where it is superior to ADA), or in combination with 
CH50 and/or ADA. 
2 A good correlation also exists between the levels of 
circulating complexes and the severity of the acute 
attack. While of prognostic value for the immediate 
attack, the long~terrn effect of high levels of circu-





















Evidence has also been presented that DNA-IC is of 
predictive value in that its appearance in the circu-
lation in a substantial number of cases antedates the 
onset of active disease. Until more data is available 
the appearance of DNA-IC alone is not considered to 
be an indication for instituting corticosteroid or 
immunosuppressive therapy. 
The specificity of the assay for SLE has been dis-
cussed in Section III . 
This data reinforces the belief that DNA is an inportant 
i.mmunogen in SLE. 
is not challenged. 
The participation of other IC systems 
The nature and molecular weight of 
DNA involved in complex formation remains to be determined. 
Indirect evidence supporting the suggestion of Bruneau et 
al (123) that the DNA involved in complex formation is of 
low molecular weight was the failure to demonstrate free 
high molecular weight DNA in the majority of our patients 
with SLE. However in order to resolve the question, the 
size and nature of the DNA actually present in the IC's 
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